<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1006832</article-id>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-18-01500</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Regression analysis</subject><subj-group><subject>Linear regression analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Regression analysis</subject><subj-group><subject>Linear regression analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Carcinomas</subject><subj-group><subject>Adenocarcinomas</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject><subj-group><subject>Squamous cell lung carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Carcinomas</subject><subj-group><subject>Squamous cell carcinomas</subject><subj-group><subject>Squamous cell lung carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Breast tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic cancer research</subject><subj-group><subject>Cancer genomics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genomic medicine</subject><subj-group><subject>Cancer genomics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene identification and analysis</subject><subj-group><subject>Genetic networks</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and information sciences</subject><subj-group><subject>Network analysis</subject><subj-group><subject>Genetic networks</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Head and neck cancers</subject><subj-group><subject>Head and neck tumors</subject><subj-group><subject>Head and neck squamous cell carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Carcinomas</subject><subj-group><subject>Squamous cell carcinomas</subject><subj-group><subject>Head and neck squamous cell carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Carcinomas</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Pan-cancer association of a centrosome amplification gene expression signature with genomic alterations and clinical outcome</article-title>
<alt-title alt-title-type="running-head">Pan-cancer landscape of centrosome amplification</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6084-6775</contrib-id>
<name name-style="western">
<surname>de Almeida</surname>
<given-names>Bernardo P.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3070-6448</contrib-id>
<name name-style="western">
<surname>Vieira</surname>
<given-names>André F.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Paredes</surname>
<given-names>Joana</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bettencourt-Dias</surname>
<given-names>Mónica</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1215-0538</contrib-id>
<name name-style="western">
<surname>Barbosa-Morais</surname>
<given-names>Nuno L.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>IPATIMUP - Instituto de Patologia e Imunologia Molecular, Universidade do Porto, Porto, Portugal</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Instituto Gulbenkian de Ciência, Oeiras, Portugal</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Kann</surname>
<given-names>Maricel G</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Maryland Baltimore County, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">nmorais@medicina.ulisboa.pt</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2019</year>
</pub-date>
<volume>15</volume>
<issue>3</issue>
<elocation-id>e1006832</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>de Almeida et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1006832"/>
<abstract>
<p>Centrosome amplification (CA) is a common feature of human tumours and a promising target for cancer therapy. However, CA’s pan-cancer prevalence, molecular role in tumourigenesis and therapeutic value in the clinical setting are still largely unexplored. Here, we used a transcriptomic signature (CA20) to characterise the landscape of CA-associated gene expression in 9,721 tumours from The Cancer Genome Atlas (TCGA). CA20 is upregulated in cancer and associated with distinct clinical and molecular features of breast cancer, consistently with our experimental CA quantification in patient samples. Moreover, we show that CA20 upregulation is positively associated with genomic instability, alteration of specific chromosomal arms and C&gt;T mutations, and we propose novel molecular players associated with CA in cancer. Finally, high CA20 is associated with poor prognosis and, by integrating drug sensitivity with drug perturbation profiles in cell lines, we identify candidate compounds for selectively targeting cancer cells exhibiting transcriptomic evidence for CA.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Centrosome amplification, i.e. an increased number of centrosomes—structures that exist inside cells, is a hallmark of cancer cells and therefore an Achilles' heel for the development of innovative therapies that specifically target tumour cells, sparing healthy ones. To exploit centrosome amplification’s clinical potential, it is crucial to understand its role in cancer development and to identify compounds for its selective targeting. These are challenging tasks due to the technical difficulty of profiling centrosome amplification in cells. In this study, we circumvent those challenges by computationally analysing the expression of 20 genes known to promote centrosome amplification across nearly 10,000 tumours of over 30 cancer types, thereby estimating their relative centrosome amplification levels. We found that those genes are indeed highly active in tumours and associated with prognosis in different cancer types. We also show that those genes’ expression is associated with instability in the structure of cancer cells’ chromosomes and identify candidate drugs for selectively targeting those cells. Our work therefore demonstrates the potential of computational analyses of large volumes of cancer molecular and clinical data to elucidate cellular and molecular mechanisms of tumour development and propose novel therapeutic options in oncology.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Fundação para a Ciência e a Tecnologia (PT)</institution>
</funding-source>
<award-id>SFRH/BPD/90303/2012</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3070-6448</contrib-id>
<name name-style="western">
<surname>Vieira</surname>
<given-names>André F.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>Fundação para a Ciência e a Tecnologia (PT)</institution>
</funding-source>
<award-id>POCI-01-0145-FEDER-01639</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bettencourt-Dias</surname>
<given-names>Mónica</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Fundação para a Ciência e a Tecnologia (PT)</institution>
</funding-source>
<award-id>PTDC/BIM-ONC/6858/2014</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bettencourt-Dias</surname>
<given-names>Mónica</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010663</institution-id>
<institution>H2020 European Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>ERC-2010-StG-261344</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bettencourt-Dias</surname>
<given-names>Mónica</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution>European Molecular Biology Organization (DE)</institution>
</funding-source>
<award-id>EMBO Installation Grant 3057</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1215-0538</contrib-id>
<name name-style="western">
<surname>Barbosa-Morais</surname>
<given-names>Nuno L.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution>Fundação para a Ciência e a Tecnologia (PT)</institution>
</funding-source>
<award-id>IF/00595/2014</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1215-0538</contrib-id>
<name name-style="western">
<surname>Barbosa-Morais</surname>
<given-names>Nuno L.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>FCT-Harvard Medical School Program Portugal</institution>
</funding-source>
<award-id>HMSP-CT/SAU-ICT/0075/2009</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bettencourt-Dias</surname>
<given-names>Mónica</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was funded by UID/BIM/50005/2019, project funded by Fundação para a Ciência e a Tecnologia (FCT) / Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) (<ext-link ext-link-type="uri" xlink:href="https://www.fct.pt/index.phtml.en" xlink:type="simple">https://www.fct.pt/index.phtml.en</ext-link>) through Fundos do Orçamento de Estado. A.F.V. is a FCT fellow (SFRH/BPD/90303/2012). The M.B-D. laboratory is supported by IGC (<ext-link ext-link-type="uri" xlink:href="http://www.igc.gulbenkian.pt/" xlink:type="simple">http://www.igc.gulbenkian.pt/</ext-link>), an EMBO Installation grant (<ext-link ext-link-type="uri" xlink:href="http://embo.org/funding-awards/installation-grants" xlink:type="simple">http://embo.org/funding-awards/installation-grants</ext-link>), ERC grant ERC-2010-StG-261344 (<ext-link ext-link-type="uri" xlink:href="https://erc.europa.eu/funding/starting-grants" xlink:type="simple">https://erc.europa.eu/funding/starting-grants</ext-link>), FCT grants (Investigador FCT to M.B-D., POCI-01-0145-FEDER-016390 and PTDC/BIM-ONC/6858/2014) and a FCT-Harvard Medical School Program Portugal grant (HMSP-CT/SAU-ICT/0075/2009) (<ext-link ext-link-type="uri" xlink:href="https://postgraduateeducation.hms.harvard.edu/" xlink:type="simple">https://postgraduateeducation.hms.harvard.edu/</ext-link>). N.L.B-M. is supported by an EMBO Installation Grant (3057) and an Investigador FCT Starting Grant (IF/00595/2014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="0"/>
<page-count count="31"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>The centrosome, an organelle composed of two centrioles surrounded by a pericentriolar protein matrix, is the major microtubule-organising centre of animal cells, hence being pivotal for several fundamental cellular processes, including signalling, cell polarity, division and migration [<xref ref-type="bibr" rid="pcbi.1006832.ref001">1</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref004">4</xref>]. Each centrosome duplicates once per cell cycle to ensure bipolar spindle assembly and successful chromosome segregation [<xref ref-type="bibr" rid="pcbi.1006832.ref005">5</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>]. Centrosomes are thus implicated in the maintenance of genome stability.</p>
<p>Centrosome amplification (CA)–the presence of more than two centrosomes—is a common feature in cancer [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>]. Supernumerary centrosomes generate multipolar mitosis and consequent genome instability [<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref008">8</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref010">10</xref>], they can accelerate and promote tumourigenesis <italic>in vivo</italic> [<xref ref-type="bibr" rid="pcbi.1006832.ref011">11</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref013">13</xref>] and promote cellular invasion and metastatic behaviour [<xref ref-type="bibr" rid="pcbi.1006832.ref014">14</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref017">17</xref>]. However, CA’s pan-cancer prevalence, molecular role in tumourigenesis and therapeutic value remain poorly understood, largely due to the technical challenges associated with profiling such small cellular structures in human cancer tissues. For instance, quantifying centrosome numbers and abnormalities is often hampered by the limited thickness of formalin-fixed and paraffin-embedded tissue sections, preventing the imaging of entire cells [<xref ref-type="bibr" rid="pcbi.1006832.ref018">18</xref>]. In addition, three-dimensional imaging and analysis are mandatory, but cumbersome and time consuming [<xref ref-type="bibr" rid="pcbi.1006832.ref019">19</xref>].</p>
<p>To at least partially circumvent those challenges, we propose the estimation of CA based on the expression levels of CA-associated genes. Recently, proof-of-principle gene-expression-based CA signatures have been developed [<xref ref-type="bibr" rid="pcbi.1006832.ref020">20</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>], the most comprehensive one being CA20, based on the expression of <italic>TUBG1</italic>, which encodes the most abundant centrosomal protein, and 19 other genes whose overexpression has been experimentally shown to induce CA [<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>]. This signature was proposed to reflect CA levels in tumour samples and shown to have a prognostic value in two independent breast cancer cohorts [<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>].</p>
<p>In the present study, we used CA20 to estimate relative CA levels across 9,721 tumour and 725 matched-normal samples of 32 cancer types from The Cancer Genome Atlas (TCGA), thereby revealing the first pan-cancer landscape of CA-associated gene expression. We show the association of CA20 with distinct breast cancer clinical and molecular features. We also break down the independent associations of CA20 with different sorts of genomic instability across cancer types. Finally, we show that high CA20 is associated with poor clinical outcome in different cancer types, having identified candidate compounds for selectively targeting cancer cells exhibiting transcriptomic evidence for this hallmark of cancer.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>The pan-cancer landscape of centrosome amplification-associated gene expression</title>
<p>To estimate relative CA levels in human samples, we used CA20, a score based on the expression of 20 genes experimentally associated with CA [<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>], as a surrogate. We quantified CA20 across the transcriptomes (profiled by RNA-seq) of 9,721 tumour and 725 matched-normal samples spanning 32 cancer types from TCGA (<xref ref-type="fig" rid="pcbi.1006832.g001">Fig 1a</xref>, <xref ref-type="supplementary-material" rid="pcbi.1006832.s018">S1 Table</xref>). CA20 correlates with the predicted proliferation rates of TCGA tumour samples [<xref ref-type="bibr" rid="pcbi.1006832.ref024">24</xref>] (Spearman’s correlation coefficient, r = 0.4, p-value &lt; 2.2e-16; <xref ref-type="supplementary-material" rid="pcbi.1006832.s001">S1a Fig</xref>), as expected, given that some of the CA20 genes encode for proteins involved in cell proliferation. Cervical (CESC), testicular (TGCT) and oesophageal (ESCA) cancers show high CA20, contrasting with lower scores in kidney (KIRP, KICH and KIRC) and prostate (PRAD) cancers (<xref ref-type="fig" rid="pcbi.1006832.g001">Fig 1b</xref>). Some cancer types, such as low-grade glioma (LGG) and breast invasive carcinoma (BRCA), exhibit high variability of CA20, concordantly with previous observations that the proportion of cells with CA in breast tumours ranges from 1 to 100% [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref025">25</xref>] depending on the tumour subtype [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>].</p>
<fig id="pcbi.1006832.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g001</object-id>
<label>Fig 1</label>
<caption>
<title>The pan-cancer landscape of centrosome amplification-associated gene expression.</title>
<p>(<bold>a</bold>) For each sample, the CA20 score was calculated as the sum of the normalized (log2 median-centred) expression levels of the 20 signature genes. (<bold>b</bold>) CA20 score distribution across tumour samples of all TCGA cancer types. Cohorts are ordered by their median CA20 score. Black points and lines represent the median +/- upper/lower quartiles. (<bold>c</bold>) Tumour samples have higher CA20 levels in all 15 cancers with both tumour and matched-normal samples available (at least 10 samples per sample type; False Discovery Rate (FDR) &lt; 0.0001, Wilcoxon rank-sum test). CA20 score distributions of tumour and normal samples are represented in red and blue, respectively. ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COADREAD: colon and rectum adenocarcinoma; DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: oesophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LGG: low-grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumours; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; UVM: uveal melanoma.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g001" xlink:type="simple"/>
</fig>
<p>We also observed significant differences in CA20 between specific cancer types with the same tissue of origin. Although all kidney cancers have low CA20 scores, kidney renal papillary cell carcinoma (KIRP) shows a lower score than the other types (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s001">S1b Fig</xref>). Similarly, glioblastoma multiforme (GBM), skin cutaneous melanoma (SKCM) and lung squamous cell carcinoma (LUSC) show higher CA20 than low-grade glioma (LGG), uveal melanoma (UVM) and lung adenocarcinoma (LUAD), respectively (p-value &lt; 0.0001 for all comparisons, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s001">S1b Fig</xref>). We note that squamous cell carcinomas have higher CA20 within cervical (CESC) and oesophageal (ESCA) cancers (p-value &lt; 0.001 and &lt; 0.01, respectively, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s001">S1c Fig</xref>), suggesting that the observed differences are indeed associated to the different cell types of origin and not only to differences between tissue of origin.</p>
<p>Since CA has been considered a hallmark of tumour cells [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>], we tested the difference of CA20 between tumour and matched-normal samples. Indeed, tumour samples have higher CA20 levels in all 15 cancer types with both sample types available (at least 10 samples of each type; False Discovery Rate (FDR) &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g001">Fig 1c</xref>). In addition, using linear regression analyses with proliferation rate as an additional covariate, we found that CA20 is higher in tumour samples, either when considering all cohorts together (linear regression p-value &lt; 0.0001, using cohort as an additional covariate; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>) or per individual cohort (FDR &lt; 0.0001 for all cohorts; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>), independently of proliferation rate, discarding the suggestion of CA20 being its mere surrogate. These results emphasise CA as a hallmark of cancer.</p>
</sec>
<sec id="sec004">
<title>CA20 is associated with breast cancer clinical and molecular features</title>
<p>Breast cancer is one of the best studied cancer types, with large cohorts of clinically annotated tumour samples available [<xref ref-type="bibr" rid="pcbi.1006832.ref027">27</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>], and where the CA20 score was developed [<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>]. In addition, CA has been frequently correlated with aggressive features in breast cancer [<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref025">25</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref029">29</xref>]. Given that we observed high variability of CA20 in TCGA breast tumour samples, we sought to investigate in more detail the relationship between CA20 and different breast cancer molecular features in that cohort.</p>
<p>CA20 is higher in tumours than in normal breast samples (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2a</xref>) and we found higher levels of CA20 in invasive tumours from ductal histologic subtype (the most common, accounting for 90% of tumours) [<xref ref-type="bibr" rid="pcbi.1006832.ref030">30</xref>] when compared with lobular ones (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2b</xref>). The difference between ductal and lobular subtypes is consistent in non-triple negative breast tumours (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2d Fig</xref>), as well as in samples from tumour stages II and III (p-value &lt; 0.0001 and &lt; 0.01, respectively, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2e Fig</xref>). We also tested the differences in CA20 between the different PAM50 molecular subtypes, derived based on a 50-gene classifier [<xref ref-type="bibr" rid="pcbi.1006832.ref031">31</xref>]. Basal-like breast tumours have the highest CA20 scores (p-value &lt; 0.0001, p-value &lt; 0.0001, and p-value &lt; 0.001 for contrasts with luminal A, luminal B, and HER2-enriched, respectively, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2c</xref>). This is in line with our recent work experimentally showing that basal-like breast cancers have indeed more CA than luminal ones [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>]. We also observed a strong difference between luminal subtypes, with higher CA20 in luminal B samples (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2c</xref>). Moreover, we tested the association between CA20 and tumour stage, having found a significant CA20 increase from stage I to stage II (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2d</xref>), but no significant changes between subsequent stages (<xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2d</xref>). All associations between CA20 and breast cancer histology, PAM50 molecular subtypes and tumour stage remain significant within both low and high proliferating tumours (samples divided by the median of estimated proliferation rates; <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2a–S2c Fig</xref>).</p>
<fig id="pcbi.1006832.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g002</object-id>
<label>Fig 2</label>
<caption>
<title>CA20 is associated with different breast cancer clinical and molecular features.</title>
<p><bold>(a-h)</bold> CA20 score distribution per (<bold>a</bold>,<bold>e</bold>) sample type, (<bold>b</bold>,<bold>f</bold>) histological and (<bold>c</bold>,<bold>g</bold>) PAM50 molecular subtype, and (<bold>d</bold>,<bold>h</bold>) tumour stage for (<bold>a</bold>-<bold>d</bold>) TCGA breast cancer and (<bold>e</bold>-<bold>h</bold>) METABRIC samples. Black points and lines represent the median +/- upper/lower quartiles. Number of samples used in each violin is shown within brackets. *** p-value &lt; 0.001, **** p-value &lt; 0.0001 and n.s. non-significant (Wilcoxon rank-sum test). <bold>(i-j)</bold> Luminal B and basal-like human breast carcinomas display higher levels of centrosome amplification (CA). <bold>(i)</bold> Illustration of the procedure to quantify CA in patient samples. <bold>(j)</bold> Percentage of cells displaying CA in breast tumours from the different PAM50 molecular subtypes (29 luminal A, 3 luminal B, 3 HER2 and 13 basal-like). Between 5 and 107 cells were analysed for each patient. * p-value &lt; 0.05, *** p-value &lt; 0.001 and n.s. non-significant (Wilcoxon rank-sum test).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g002" xlink:type="simple"/>
</fig>
<p>All the aforementioned associations were validated in an independent cohort (<xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2e–2h</xref>, <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2f and S2g Fig</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s020">S3 Table</xref>), comprising 144 normal and 1,992 tumour breast samples from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>]. We still tested the association between CA20 and the METABRIC integrative clusters, 10 molecular subgroups defined based on joint clustering of copy number and gene expression data [<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>]. CA20 varies across integrative clusters (p-value &lt; 0.0001, Fligner-Killeen test) and is particularly enriched in cluster 10 (FDR &lt; 0.0001, Wilcoxon rank-sum test, for comparisons with each of all the other clusters; <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2h Fig</xref>), characterized by high proportion of basal-like tumours, high genomic instability, high rate of <italic>TP53</italic> mutations, chromosome arm 5q deletions and very poor prognosis in the short term [<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>].</p>
<p>We complementarily analysed the frequency of CA in human breast carcinomas from the different PAM50 molecular subtypes, comprising 29 luminal A, 3 luminal B, 3 HER2 and 13 basal-like tumours (<xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2i</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s021">S4 Table</xref>). Concordantly with TCGA and METABRIC results, we observed a higher percentage of cells with supernumerary centrioles in luminal B (average of 27%) than in luminal A carcinomas (7%; p-value &lt; 0.05, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2j</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s003">S3 Fig</xref>). Moreover, basal-like (25%) display higher levels of CA than luminal A tumours (p-value &lt; 0.0001, Wilcoxon rank-sum test). Despite the reduced number of luminal B samples, our patient data support CA20 as a good surrogate of CA levels and the suggestion that CA is more frequent in luminal B than in luminal A human breast carcinomas.</p>
</sec>
<sec id="sec005">
<title>CA20 is associated with genomic instability features in cancer</title>
<p>CA and consequent multipolar mitoses have been associated with aneuploidy, genomic instability and tumourigenesis for more than a century [<xref ref-type="bibr" rid="pcbi.1006832.ref032">32</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref033">33</xref>]. Using the available quantitative characterization of aneuploidy in TCGA [<xref ref-type="bibr" rid="pcbi.1006832.ref034">34</xref>], we found that CA20 is higher in samples with genome doubling (p-value &lt; 0.0001, Wilcoxon rank-sum test; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3a</xref>) and positively correlated with their aneuploidy score (measured as the total number of altered—gained or lost—chromosome arms; Spearman’s correlation coefficient, r = 0.44, p-value &lt; 2.2e-16; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3b</xref>). Although CA20 is positively correlated with both chromosomal deletions and amplifications (Spearman’s correlation coefficient, r = 0.41 and 0.36, p-value &lt; 2.2e-16, respectively; <xref ref-type="supplementary-material" rid="pcbi.1006832.s004">S4a and S4b Fig</xref>), it is more strongly associated with chromosomal deletions (p-value &lt; 2.2e-16, t-test for z-transformed coefficients; see also <xref ref-type="supplementary-material" rid="pcbi.1006832.s004">S4c Fig</xref>). Given the known association between loss of p53 and CA [<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref035">35</xref>] and the recent observation that p53 null cells tend to have an enrichment of chromosome losses over gains [<xref ref-type="bibr" rid="pcbi.1006832.ref036">36</xref>], we tested the hypothesis that the observed association between CA20 and chromosomal deletions could be linked to <italic>TP53</italic> mutations. However, the increase in the proportion of deletions per sample from low to high CA20 samples is consistent within both <italic>TP53</italic> wild-type and mutated samples (p-value &lt; 0.0001 and &lt; 0.05, respectively, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s004">S4d and S4e Fig</xref>), showing it is independent of <italic>TP53</italic> mutations (two-way ANOVA p-value for interaction = 0.6; <xref ref-type="supplementary-material" rid="pcbi.1006832.s004">S4d Fig</xref>).</p>
<fig id="pcbi.1006832.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g003</object-id>
<label>Fig 3</label>
<caption>
<title>CA20 is associated with genomic instability features in cancer.</title>
<p>(<bold>a</bold>) CA20 score is associated with genome doubling. Box plots of CA20 score per whole genome doubling status. **** p-value &lt; 0.0001 (Wilcoxon rank-sum test). (<bold>b</bold>, <bold>d</bold>-<bold>f</bold>) CA20 is associated with different genomic instability features. Smooth scatter plots showing correlation between CA20 score and (<bold>b</bold>) aneuploidy score (measured as the total number of altered chromosome arms), (<bold>d</bold>) number of mutations per Mb, (<bold>e</bold>) number of CNAs and (<bold>f</bold>) clones per tumour across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.44, 0.48, 0.47 and 0.43, respectively, p-value &lt; 2.2e-16 for all). (<bold>c</bold>) Chromosome arm alterations associated with CA20 score. Volcano plot shows the results of linear regression analyses comparing CA20 score between samples with deletion or amplification of each chromosome arm. Arms whose deletions or amplifications are associated with higher CA20 (FDR &lt; 0.05) are represented in blue and red, respectively. Chromosome arms with FDR &lt; 1e-5 are highlighted and box plots of CA20 score per chromosome arm alteration are shown for 5q, 16p and 7p arms. **** p-value &lt; 0.0001 (linear regression). (<bold>g</bold>) Hierarchical clustering of TCGA cancer types based on the independent association between the different genomic instability features and CA20 score. Unsupervised hierarchical clustering using Euclidean distances calculated based on multiple linear regression p-values of association with CA20 of aneuploidy score, number of mutations per Mb, number of CNAs and clones per tumour, per TCGA cohort and with all cohorts together (PanCancer). Heatmap colour scale according with -log10 of linear regression p-values. Main clusters are highlighted with different shades of grey. BLCA: bladder urothelial carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; LGG: low-grade glioma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PRAD: prostate adenocarcinoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; THCA: thyroid carcinoma.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g003" xlink:type="simple"/>
</fig>
<p>Investigating the hypothesis that CA20-associated aneuploidy levels could vary between chromosomes, we identified 20 chromosome arms whose deletion (10 arms) or amplification (10 arms) was enriched in tumour samples with higher CA20 (linear regression, FDR &lt; 0.05; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3c</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s022">S5</xref> Tables). The strongest associations were with loss of 5q, 16p and 7p. Interestingly, 5q deletion was previously associated with CA20-high basal-like breast tumours [<xref ref-type="bibr" rid="pcbi.1006832.ref027">27</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref037">37</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref040">40</xref>] and METABRIC integrative cluster 10 [<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>] (<xref ref-type="fig" rid="pcbi.1006832.g002">Fig 2c and 2g</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s002">S2h Fig</xref>). The association between CA20 and 5q deletion remains when removing the breast cancer cohort (linear regression p-value &lt; 2.2e-16; <xref ref-type="supplementary-material" rid="pcbi.1006832.s005">S5 Fig</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). This observation raises the question if matched-normal samples of the analysed tumour samples have a CA20 signal predictive of those 5q, 16p and 7p deletions. We tested this hypothesis by comparing the CA20 levels between normal samples (with intact tested chromosomal arms) whose matched tumours lost 5q, 16p or 7p, with those with tumours with amplifications or no alterations in those chromosomal arms. We found that normal samples whose matched tumours lost 5q or 16p exhibit higher CA20 scores (p-value &lt; 0.01 and &lt; 0.05, respectively, Wilcoxon rank-sum test; <xref ref-type="supplementary-material" rid="pcbi.1006832.s006">S6 Fig</xref>), therefore suggesting that a CA20 increase may precede those chromosomal abnormalities.</p>
<p>In addition to tumour aneuploidy, CA20 is positively correlated with mutation burden, number of somatic Copy Number Alterations (CNA) and number of clones per tumour (Spearman’s correlation coefficient, r = 0.48, 0.47 and 0.43, respectively, p-value &lt; 2.2e-16 for all; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3d–3f</xref>). All these associations are independent of cell proliferation (linear regression p-values &lt; 1e-8 for all; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s007">S7 Fig</xref>). We found that the correlation with mutation burden holds for different types of mutations (silent, missense, splice site and nonsense), as well as for mutations shown to be pathogenic (data from ClinVar <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" xlink:type="simple">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>) in all diseases and particularly in cancer (<xref ref-type="supplementary-material" rid="pcbi.1006832.s008">S8 Fig</xref>). Since these genomic instability features are likely correlated between each other, we applied multiple linear regression analyses across 1050 tumour samples (from 12 different cancer types; minimum of 30 and average of 88 samples per cohort) with information for those 4 covariates (<xref ref-type="supplementary-material" rid="pcbi.1006832.s023">S6 Table</xref>). We identified independent positive associations between CA20 and all genomic instability features, with stronger association for CNAs (linear regression p-values = 1.3e-5, 7.2e-4, 5.3e-10 and 6.4e-3 for aneuploidy, mutation burden, CNA and number for clones, respectively; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3g</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). These associations remain significant when proliferation rate is used as an additional covariate in the regression (p-values = 2.3e-5, 7e-4, 2.4e-9 and 0.03 for aneuploidy, mutation burden, CNA and number for clones, respectively; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). We performed similar analyses per TCGA cohort and identified a group of cancer types where CA20 is mostly associated with CNA and aneuploidy (prostate adenocarcinoma, glioblastoma multiforme, bladder urothelial carcinoma, and brain low-grade glioma; <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3g</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s009">S9 Fig</xref>; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). Although CA has been globally associated with genomic instability, these results highlight CNA as the main associated feature and show that these associations differ between cancer types.</p>
</sec>
<sec id="sec006">
<title>CA20 is associated with cancer’s mutational spectrum</title>
<p>Point mutations are one of the most common types of mutational events that impact the stability of a cancer genome. We examined the pan-cancer association between CA20 and somatic mutations in 14,589 genes and found 752 whose mutations are associated with CA20 (FDR &lt; 0.05; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s024">S7</xref> Tables). Most significant associations of mutated genes with the CA20 score are positive, consistently with its correlation with higher mutation burden (<xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3d</xref>), and enriched in cancer driver genes (Gene Set Enrichment Analysis (GSEA) [<xref ref-type="bibr" rid="pcbi.1006832.ref041">41</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref042">42</xref>] p-value &lt; 0.001, using a list of 299 cancer driver genes derived from TCGA’s PanCancer analysis [<xref ref-type="bibr" rid="pcbi.1006832.ref043">43</xref>]; <xref ref-type="supplementary-material" rid="pcbi.1006832.s010">S10a Fig</xref>). <italic>TP53</italic> shows the strongest association (linear regression p-value &lt; 0.0001; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>), with positive correlations for the majority of cancer types surveyed (10 out of 17 cancer types with at least 20 mutated samples; FDR &lt; 0.05; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4b</xref>), therefore putatively extending the reported association between loss of p53 and CA [<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref035">35</xref>] to 10 different cancer types. The second strongest positive association is with tumour suppressor pRb (<italic>RB1</italic>), whose acute loss has been found to induce CA [<xref ref-type="bibr" rid="pcbi.1006832.ref044">44</xref>]. Unexpectedly, the strongest negative association is with E-cadherin (encoded by <italic>CDH1</italic>), meaning <italic>CDH1</italic>-mutated samples have lower CA20 levels. Given its tumour suppressor role in cancer and the fact that its mutations mostly induce loss of function [<xref ref-type="bibr" rid="pcbi.1006832.ref045">45</xref>], this result suggests loss of E-cadherin is associated with lower CA in human tumours, which is contrary to what have been reported in epithelial cancer cells [<xref ref-type="bibr" rid="pcbi.1006832.ref046">46</xref>]. GSEA on genes whose mutations are associated with CA20 found that they are enriched in cancer-associated pathways and Wnt/β-catenin signalling (<xref ref-type="supplementary-material" rid="pcbi.1006832.s010">S10c–S10f Fig</xref>). As only a small fraction of somatic mutations represent driver events, we repeated the pan-cancer analysis of association between CA20 and somatic mutations using likely driver mutations from the Cancer Genome Interpreter (<ext-link ext-link-type="uri" xlink:href="https://www.cancergenomeinterpreter.org/mutations" xlink:type="simple">https://www.cancergenomeinterpreter.org/mutations</ext-link>) [<xref ref-type="bibr" rid="pcbi.1006832.ref045">45</xref>]. Within the tested 33 genes with at least 10 mutated samples, we found three (<italic>TP53</italic>, <italic>PIK3CA</italic> and <italic>EGFR</italic>) whose driver mutations are associated with CA20 (FDR &lt; 0.05; <xref ref-type="supplementary-material" rid="pcbi.1006832.s010">S10b Fig</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s025">S8</xref> Tables), <italic>TP53</italic> being again the strongest association. Overall, we show that CA20 is associated with both passenger and driver mutational spectra in cancer, with particular enrichment in cancer driver genes and Wnt/β-catenin signalling.</p>
<fig id="pcbi.1006832.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g004</object-id>
<label>Fig 4</label>
<caption>
<title>CA20 is associated with cancer’s mutational spectrum.</title>
<p>(<bold>a</bold>) Somatic mutations pan-cancer-wide associated with the CA20 score. The volcano plot shows the results of linear regression analyses comparing the CA20 score between mutated and wild-type samples for 14,589 genes (at least 20 mutated samples). Genes whose mutations are associated with higher and lower CA20 (FDR &lt; 0.05) are represented in red and blue, respectively. The top 10 genes are highlighted. (<bold>b</bold>) <italic>TP53</italic> mutations are associated with CA20 in different cancer types. Linear regression coefficients, representing CA20 score differences between <italic>TP53</italic> mutated and wild-type tumour samples, across TCGA cohorts with at least 20 mutated samples. Significant associations (FDR &lt; 0.05) are coloured as in (a). (<bold>c</bold>) Mutational signatures pan-cancer-wide associated with CA20, independently of other types of genomic instability. Left: Significance of linear regression analyses (-log10 p-value) between CA20 and contribution of each mutational signatures including, as independent variables, the four genomic instability features: aneuploidy, mutation burden, CNA and number of clones per tumour. Positive and negative significant associations (FDR &lt; 0.05) are coloured in red and blue, respectively. Right: Smooth scatter plots showing correlations between CA20 and the contribution of mutational signature 1 (linked with ageing) in 3 TCGA cohorts. Linear regression p-values are shown. (<bold>d</bold>) Causal effect of CA20-associated mutations on CA20 levels. Scatter plot of linear regression’s coefficient from (a) versus Connectivity Map (CMap)’s knock-down score, ranging from 100 (CA20 up-regulation) to -100 (CA20 down-regulation), for each gene in common. Genes are coloured as in (a) and the ones with both significant linear regression associations and absolute knock-down score higher than 80 are highlighted. (<bold>e</bold> and <bold>f</bold>) Gene Set Enrichment Analysis (GSEA) of genes ranked by their CMap’s knock-down score using (<bold>e</bold>) a manually curated list of centriole duplication factors and (<bold>f</bold>) MSigDB’s Hallmark Gene Sets (unfolded protein response and mitotic spindle were significantly associated, FDR &lt; 0.05). GSEA p-values are shown. BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; ESCA: oesophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; LGG: low-grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; UCS: uterine carcinosarcoma.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g004" xlink:type="simple"/>
</fig>
<p>CA has still been proposed as a driver of genomic instability [<xref ref-type="bibr" rid="pcbi.1006832.ref011">11</xref>]. We thus wondered if the DNA mutation spectrum associated with CA was similar to specific signatures of somatic mutations caused by different mutational processes in cancer [<xref ref-type="bibr" rid="pcbi.1006832.ref047">47</xref>]. We therefore retrieved the contribution of the 30 published mutational signatures for each TCGA tumour sample from mSignatureDB [<xref ref-type="bibr" rid="pcbi.1006832.ref048">48</xref>] and uncovered three of them positively associated with CA20: signature 3, associated with BRCA1/2 mutations; signature 13, attributed to APOBEC activity; and signature 4, characteristic of smoking’s mutational pattern (FDR &lt; 0.05; <xref ref-type="supplementary-material" rid="pcbi.1006832.s011">S11 Fig</xref>). As these signatures are likely confounded with genomic instability, we performed multiple linear regression on CA20 including, as independent variables, the mutational signature and the four aforementioned genomic instability features: aneuploidy, mutation burden, CNA and number of clones per tumour (<xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). Signature 1, linked with ageing and characterised by C&gt;T substitutions (<xref ref-type="supplementary-material" rid="pcbi.1006832.s012">S12a Fig</xref>), and its “reverse” (T&gt;C substitution bias) Signature 12, found mainly in liver cancer (<xref ref-type="supplementary-material" rid="pcbi.1006832.s012">S12b Fig</xref>), are respectively positively and negatively associated (FDR &lt; 0.05) with CA20 (<xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4c</xref>), independently of other types of genomic instability and even when proliferation rate is added as a variable (FDR = 0.051 for both signatures).</p>
<p>To evaluate the putative causality of CA20-associated mutations (<xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>), we interrogated the Connectivity Map (CMap) database of signatures [<xref ref-type="bibr" rid="pcbi.1006832.ref049">49</xref>] about the impact of each of the 3,799 gene knock-downs on the CA20 gene set in human cancer cell lines. The resultant connectivity scores (<xref ref-type="supplementary-material" rid="pcbi.1006832.s026">S9 Table</xref>), ranging from 100 (CA20 up-regulation) to -100 (CA20 down-regulation), were compared with the pan-cancer association between somatic mutations in the cognate genes and CA20 (<xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4d</xref>). We thereby identified 6 genes with a putative causal effect on CA20 scores (|connectivity score| &gt; 80; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4d</xref>): <italic>P2RY12</italic>, <italic>RB1</italic>, <italic>ITSN1</italic> and <italic>MYCBP2</italic> are putative inhibitors of CA (their knock-down up-regulate CA20 genes), whereas <italic>ABCC5</italic> and <italic>COPA</italic> are putative promoters of CA (their knock-down down-regulate CA20 genes). Although acute loss of pRb (encoded by <italic>RB1</italic>) has been found to induce CA [<xref ref-type="bibr" rid="pcbi.1006832.ref044">44</xref>], confirming pRb as a CA inhibitor, to our knowledge none of the remaining genes identified herein has been previously associated with CA. They are therefore interesting candidates for future functional studies. Genes from a manually curated list of centriole duplication factors (93 genes, including only 10 from the CA20 signature; <xref ref-type="supplementary-material" rid="pcbi.1006832.s027">S10 Table</xref>) are enriched in negative CMap knock-down scores (GSEA p-value &lt; 0.001; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4e</xref>), suggesting they are indeed needed for cells to express CA-associated genes. Using the MSigDB’s Hallmark Gene Sets library [<xref ref-type="bibr" rid="pcbi.1006832.ref050">50</xref>], we identified unfolded protein response and mitotic spindle as significantly enriched in genes whose knock-down showed negative scores, i.e. CA20 down-regulation (GSEA FDR &lt; 0.05; <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4f</xref>). This association suggests that mitotic spindle components activate CA-associated genes and/or that cells highly expressing CA-associated genes may be less likely to survive when their mitotic spindle is perturbed.</p>
</sec>
<sec id="sec007">
<title>CA20 is associated with prognosis, hypoxia and stromal infiltration in cancer</title>
<p>CA has been associated with poor patient prognosis in a variety of cancer types [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>]. We therefore tested CA20’s association with overall patient’s survival across 31 TCGA cancer types with more than 40 samples each, finding high CA20 significantly associated with worse prognosis in 8 different cancer types (FDR &lt; 0.05, log-rank test; <xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5a</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s028">S11 Table</xref>). This result supports the potential of CA20 for prognostic-based patient stratification.</p>
<fig id="pcbi.1006832.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g005</object-id>
<label>Fig 5</label>
<caption>
<title>High CA20 is associated with poor patient prognosis, hypoxia and lower stromal infiltration in cancer.</title>
<p>(<bold>a</bold>) Kaplan-Meier plots for patient stratification based on CA20 score (patients divided by CA20 median: lower CA20 in blue and higher CA20 in red) in 8 different cancer types. Numbers at risk every 2.5 years (tables) and 5-year survival rates (points and dashed lines) are shown. P-values for log-rank tests for differences in survival are shown. (<bold>b</bold>) CA20 upregulation is associated with hypoxia. Smooth scatter plot showing correlation between the hypoxia and the CA20 scores across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.61, p-value &lt; 2.2e-16). (<bold>c</bold>) CA20 upregulation is associated with hypoxia in different cancer types. Linear regression coefficients, representing the CA20 score dependence on hypoxia score, independently of genomic instability, across the TCGA cohorts with information for all covariates. Significant associations (FDR &lt; 0.05) are coloured. (<bold>d</bold>) CA20 is associated with lower stromal cell infiltration. Smooth scatter plot showing correlation between the CA20 and the stromal scores across TCGA tumour samples (Spearman’s correlation coefficient, r = -0.52, p-value &lt; 2.2e-16). (<bold>e</bold>) CA20 is associated with lower stromal cell infiltration in head and neck squamous cell carcinoma and lung adenocarcinoma. Linear regression coefficients, representing the CA20 score dependence on stromal score, independently of genomic instability, across the TCGA cohorts with information for all covariates. Significant associations (FDR &lt; 0.05) are coloured. ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; LGG: low-grade glioma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; THCA: thyroid carcinoma; UVM: uveal melanoma.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g005" xlink:type="simple"/>
</fig>
<p>Hypoxia is a potent microenvironmental factor promoting genetic instability and malignant progression [<xref ref-type="bibr" rid="pcbi.1006832.ref051">51</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref053">53</xref>]. Given that hypoxia has been shown to enhance centrosome aberrations in breast cancer [<xref ref-type="bibr" rid="pcbi.1006832.ref054">54</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref055">55</xref>], we investigated whether CA20 is associated with the relative hypoxia levels in TCGA tumour samples, given by a previously established surrogate metagene expression signature [<xref ref-type="bibr" rid="pcbi.1006832.ref056">56</xref>]. We found a positive correlation between CA20 and the hypoxia score (Spearman’s correlation coefficient, r = 0.61, p-value &lt; 2.2e-16; <xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5b</xref>) that is independent of genomic instability (linear regression p-value = 7.8e-9; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). We further confirmed that this association is independent of estimated proliferation rates (linear regression p-value = 5.6e-7 when proliferation rate is added as a covariate to the regression; <xref ref-type="supplementary-material" rid="pcbi.1006832.s013">S13a Fig</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). We also performed this linear regression analysis for each of the 12 TCGA cohorts with information for all covariates and identified three cancer types (glioblastoma multiforme, lung adenocarcinoma and bladder urothelial carcinoma) where hypoxia is positively associated (FDR &lt; 0.05) with CA20 (<xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5c</xref>; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>).</p>
<p>Although a tumour is also composed by stromal and immune cells [<xref ref-type="bibr" rid="pcbi.1006832.ref057">57</xref>], the association between CA and tumour cellular composition has not been addressed yet. CA20 is associated with lower stromal (Spearman’s correlation coefficient, r = -0.52, p-value &lt; 2.2e-16; <xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5d</xref>) and immune (Spearman’s correlation coefficient, r = -0.34, p-value &lt; 2.2e-16; <xref ref-type="supplementary-material" rid="pcbi.1006832.s013">S13c Fig</xref>) cell infiltration in TCGA. However, pan-cancer linear regression analyses revealed that only the negative association with stromal infiltration is independent of genomic instability (linear regression p-value = 2.7e-6 and 0.24, for stromal and immune, respectively; <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). The same was observed when including proliferation rate as an additional covariate (linear regression p-value = 1.2e-4 and 0.21, respectively; <xref ref-type="supplementary-material" rid="pcbi.1006832.s013">S13b and S13d Fig</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). We have also performed similar analyses for each of the 5 TCGA cohorts with information for all covariates and found that CA20 is significantly associated (FDR &lt; 0.05) with lower stromal infiltration in head and neck and lung cancers (<xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5e</xref>), with lower immune infiltration in glioblastoma, and with higher immune infiltration in head and neck cancer (<xref ref-type="supplementary-material" rid="pcbi.1006832.s013">S13e Fig</xref>), all independently of genomic instability (<xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>).</p>
</sec>
<sec id="sec008">
<title>Identification of compounds that selectively kill cancer cells with high CA20</title>
<p>CA is a hallmark of cancer cells and hence an appealing target in cancer therapy. In order to identify compounds that could target cancer cells with such abnormality, we have employed CA20 to estimate relative CA levels in 823 human cancer cell lines from the Cancer Therapeutics Response Portal (CTRP) [<xref ref-type="bibr" rid="pcbi.1006832.ref058">58</xref>] (<xref ref-type="supplementary-material" rid="pcbi.1006832.s029">S12 Table</xref>), for which both transcriptomic and drug-sensitivity profiles are publicly available. Correlation analyses between CA20 and drug-sensitivity (in Area Under the dose-response Curve, AUC) for 354 compounds revealed 81 negatively correlated with CA20 (FDR &lt; 0.05, Spearman’s correlation; <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6a</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s030">S13 Table</xref>), i.e. higher CA20 was associated with lower drug AUC and, therefore, higher drug activity. The enrichment of negative correlations (<xref ref-type="supplementary-material" rid="pcbi.1006832.s014">S14 Fig</xref>) may reflect the bias for cancer-targeting compounds in CTRP. These results suggest several candidate compounds to selectively kill cancer cells with CA, such as 3-CI-AHPC, CD-437, STF-31, methotrexate, BI-2536 and clofarabine (<xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6b</xref>). The first three are probes, methotrexate and clofarabine are U.S. Food and Drug Administration (FDA)-approved drugs for several cancer types (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate" xlink:type="simple">https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate</ext-link>) and paediatric acute lymphoblastic leukemia (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-cancer/treatment/drugs/fda-clofarabine" xlink:type="simple">https://www.cancer.gov/about-cancer/treatment/drugs/fda-clofarabine</ext-link>), respectively. Interestingly, BI-2536 has been in clinical trials for several solid and liquid tumours (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=bi+2536&amp;cntry=&amp;state=&amp;city=&amp;dist" xlink:type="simple">https://clinicaltrials.gov/ct2/results?cond=&amp;term=bi+2536&amp;cntry=&amp;state=&amp;city=&amp;dist</ext-link>) and is an inhibitor of polo-like kinase 1 (PLK1), whose inhibition has already been associated with CA suppression [<xref ref-type="bibr" rid="pcbi.1006832.ref059">59</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref060">60</xref>].</p>
<fig id="pcbi.1006832.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006832.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Identification of compounds that selectively kill cancer cells with high CA20.</title>
<p>(<bold>a</bold>) Compounds with selective activity on cell lines with high or low CA20 score. The volcano plot shows the results of Spearman’s correlation analyses between CA20 scores and compound Area Under the dose-response Curve (AUC) across Cancer Therapeutics Response Portal (CTRP) human cancer cell lines. Note that lower AUC means higher drug activity. The compounds whose activity was associated with high and low CA20 (FDR &lt; 0.05) are represented in blue and red, respectively. The top 6 compounds are highlighted. (<bold>b</bold>) Top 6 compounds targeting cells with higher CA20 score. Smooth scatter plots showing correlation between CA20 score and compound AUC across CTRP cell lines for the top 6 compounds from (a). Spearman’s correlation coefficients, r, and respective p-values are shown. (<bold>c</bold>) Compounds that down-regulate the CA20 gene set. Heatmap of CMap’s drug score, ranging from 100 (maximum CA20 up-regulation) to -100 (maximum CA20 down-regulation) per cell line. Drug average score (last column) is the mean of drug scores across cell lines. The 20 compounds with the lowest drug average score are shown and ranked accordingly. Tissue of origin of human cancer cell lines: PC3: prostate; VCAP: prostate; A375: melanoma; A549: lung; HA1E: kidney; HCC515: lung; HT29: colon; MCF7: breast; HEPG2: liver. (<bold>d</bold>) Compounds selectively targeting cells with higher CA20 also down-regulate these genes. Scatter plot showing correlation between CTRP’s Spearman’s correlation coefficient from (a) and CMap’s drug average score from (c) for the 164 compounds tested in both datasets (Spearman’s correlation coefficient, r = 0.26, p-value = 8.3e-4). Points are coloured as in (a) and the predicted protein targets of compounds with both significant Spearman’s correlations and drug average score lower than -90 are shown.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.g006" xlink:type="simple"/>
</fig>
<p>Complementarily, we mined the CMap database to identify compounds that could impact the CA20 score and therefore putatively reduce/increase CA levels. We calculated the impact of 2,837 compounds on the CA20 transcriptomic levels in human cancer cell lines (<xref ref-type="supplementary-material" rid="pcbi.1006832.s031">S14 Table</xref>) and identified some whose activity drove CA20 up-regulation (putative CA promoters; <xref ref-type="supplementary-material" rid="pcbi.1006832.s015">S15 Fig</xref>), such as VEGFR2-kinase-inhibitor-IV, dienestrol (oestrogen receptor agonist) and sulforaphane (anticancer agent in clinical trials for Bladder, Breast, Lung and Prostate cancers; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=sulforaphane&amp;Search=Apply&amp;recrs=d&amp;age_v=&amp;gndr=&amp;type=&amp;rslt=" xlink:type="simple">https://clinicaltrials.gov/ct2/results?cond=sulforaphane&amp;Search=Apply&amp;recrs=d&amp;age_v=&amp;gndr=&amp;type=&amp;rslt=</ext-link>). We also identified compounds that down-regulated CA20, such as two CDK inhibitors (purvalanol-a and aminopurvalanol-a), JAK3-inhibitor-VI, etoposide (topoisomerase and cell cycle inhibitor) and CD-437 (agonist of RARG, retinoic acid receptor gamma; <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6c</xref>).</p>
<p>For the 164 drugs tested in both datasets, we observed a positive correlation between their CA20/sensitivity correlations in CTRP and their CMap scores (Spearman’s correlation coefficient, r = 0.26, p-value = 8.3e-4; <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6d</xref>), indicating that drugs selectively targeting cells with higher CA20 are reducing the expression of these genes, possibly by killing the abnormal cells in the tumour cell population. These complementary approaches uncovered RARG’s agonist CD-437 as the strongest candidate for targeting CA. Moreover, drugs targeting coagulation factor II (F2R), farnesyltransferase (FNTA and FNTB), ubiquitin isopeptidases (USP13 and USP5), DNA topoisomerase II alpha (TOP2A) and cyclin-dependent kinases (CDKs) are also promising candidates (<xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6d</xref>). Given cell proliferation’s association with CA20 (<xref ref-type="supplementary-material" rid="pcbi.1006832.s001">S1a Fig</xref>), we have tested the association between its estimated rates across TCGA primary tumour samples and the expression of the 164 compounds’ predicted target genes (merging this information from the CTRP (<xref ref-type="supplementary-material" rid="pcbi.1006832.s030">S13 Table</xref>) and CMap datasets (<xref ref-type="supplementary-material" rid="pcbi.1006832.s031">S14 Table</xref>)), using linear regression analyses with cohort as additional covariate (<xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>). The resultant coefficients (<xref ref-type="supplementary-material" rid="pcbi.1006832.s032">S15 Table</xref>) are not correlated with CMap’s average scores of the respective compounds (Spearman’s correlation coefficient, r = 0.016, p-value = 0.84; <xref ref-type="supplementary-material" rid="pcbi.1006832.s016">S16a Fig</xref>), but are correlated with their CTRP’s Spearman correlation coefficients (Spearman’s correlation coefficient, r = -0.26, p-value = 9e-04; <xref ref-type="supplementary-material" rid="pcbi.1006832.s016">S16b Fig</xref>), i.e. compounds selective for cells with high CA20 are predicted to target genes positively associated with proliferation in TCGA tumour samples. Nevertheless, predicted target genes of several compound candidates from our analyses do not show strong association with proliferation (<xref ref-type="supplementary-material" rid="pcbi.1006832.s016">S16c and S16d Fig</xref>). These results need to be considered when prioritizing candidate compounds for further experiments aiming to target cancer cells through CA.</p>
</sec>
</sec>
<sec id="sec009" sec-type="conclusions">
<title>Discussion</title>
<p>CA is known to promote tumourigenesis but its molecular role therein remains elusive and, although it is also suggested to be a promising target for cancer therapy, CA’s prevalence in different types of cancer and therapeutic value in the clinic are still pretty much unprobed. Using the CA20 signature and TCGA RNA-seq data, we characterise the landscape of CA-associated gene expression in a broad range of cancer types, thereby demonstrating the potential of using gene expression-based signatures in multi-omic and clinical data integrative approaches to investigate the biological and medical relevance of their respective cellular and molecular processes.</p>
<p>Despite the lack of a full direct experimental validation of CA20 as a surrogate of CA levels, our observations are very consistent with known CA’s features, namely CA20’s upregulation in cancer [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>] and in basal-like breast tumours [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>], and its association with the knock-down of centriole duplication factors, genomic instability [<xref ref-type="bibr" rid="pcbi.1006832.ref011">11</xref>], loss of p53 [<xref ref-type="bibr" rid="pcbi.1006832.ref006">6</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref035">35</xref>] and pRB [<xref ref-type="bibr" rid="pcbi.1006832.ref044">44</xref>], hypoxia [<xref ref-type="bibr" rid="pcbi.1006832.ref054">54</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref055">55</xref>] and worse patient’s prognosis [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>]. In addition, we found that luminal B breast tumours have higher prevalence of CA than luminal A ones, concordantly with the observed differences in the CA20 score between the two molecular subtypes in two independent cohorts. Finally, we have analysed two transcriptomic datasets of multiciliogenesis, where cells escape centriole number regulation to generate hundreds of centrioles during differentiation [<xref ref-type="bibr" rid="pcbi.1006832.ref061">61</xref>], and found that CA20 increases during the centriole overduplication stage, resuming basal levels afterwards (<xref ref-type="supplementary-material" rid="pcbi.1006832.s017">S17 Fig</xref>), suggesting CA20 as a marker of active amplification. These observations vouch for the present proof-of-concept study to pave the way for more in-depth and bona fide findings when CA’s transcriptomic signature is experimentally refined. Moreover, here we already propose novel hypotheses that will trigger studies aiming at a more comprehensive understanding of the role of CA in cancer.</p>
<p>We observed higher CA-associated gene expression in cancer samples of squamous cell origin than in adenocarcinomas, suggesting that their different cell types of origin can have different CA’s prevalence and/or ways to cope with this abnormality. Previous work has indeed shown that CA triggers spontaneous squamous cell carcinomas, lymphomas and sarcomas, but not adenocarcinomas, in mice [<xref ref-type="bibr" rid="pcbi.1006832.ref011">11</xref>]. We also show that breast invasive carcinoma samples have high variability on CA20, concordantly with previous observations [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref025">25</xref>], that is related to their distinct clinical and molecular features. We had recently shown that basal-like breast carcinomas have higher CA than luminal tumours [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>], but here we report for the first time an upregulation of CA-associated genes in tumours from both invasive ductal histologic subtype and luminal B molecular subtype. We validated the CA20-based predictions by quantitatively analysing centrosome numbers in human breast carcinoma samples, where we found that indeed CA is more prevalent in luminal B than luminal A tumours, providing a novel insight into the differences between these two hormone-receptor positive molecular subtypes. Given the limited number of luminal B samples in our cohort, more extensive analyses are necessary to confirm this association. Our data show that centrosome amplification is associated with breast cancer clinical features and endorses the potential of using a gene-expression-based signature for patient stratification.</p>
<p>CA-associated gene expression upregulation is positively correlated with different types of genomic instability, like aneuploidy, mutation burden, CNA and tumour heterogeneity. In particular, CA20 is more strongly associated with chromosomal deletions than amplifications, independently of <italic>TP53</italic> mutations. We speculate that this association may be due to the impact of CA in cellular genomic stability having non-random genomic “hot spots”. In fact, through a more detailed analysis, we found an association with alterations in specific chromosomal arms, that may be due to the localisation of genes encoding for regulators of CA20 genes therein and/or to those arms’ higher susceptibility to the genomic instability triggered by centrosome abnormalities. The latter is supported by recent work showing that human chromosome mis-segregation is not random and can be biased by inherent properties of individual chromosomes [<xref ref-type="bibr" rid="pcbi.1006832.ref062">62</xref>], and also by our observation that normal samples whose matched tumours lost 5q or 16p have higher CA20 predictive of those deletions (<xref ref-type="supplementary-material" rid="pcbi.1006832.s006">S6 Fig</xref>). Moreover, we characterised the DNA mutation spectrum associated with CA20 and found it to be enriched in C&gt;T mutations, a signature characteristic of ageing, with which centrosome aberrations have also been associated [<xref ref-type="bibr" rid="pcbi.1006832.ref063">63</xref>–<xref ref-type="bibr" rid="pcbi.1006832.ref067">67</xref>]. Genes whose mutations are associated with CA20 are enriched in cancer driver genes, and particularly in Wnt/β-catenin signalling. Wnt/β-catenin signalling components interact with the centrosome [<xref ref-type="bibr" rid="pcbi.1006832.ref068">68</xref>] and a previous study has demonstrated that mutant β-catenin induces centrosome aberrations in normal epithelial cells and is required for CA in cancer cells [<xref ref-type="bibr" rid="pcbi.1006832.ref069">69</xref>]. Our results extend this previous association to human cancer samples, suggesting mutations in β-catenin might contribute to the observed CA in cancer. Finally, we show the usefulness of a novel approach whereby we integrated information on genes whose somatic mutations are associated with CA20 in TCGA tumour samples with the impact of their knock-downs on the CA20 expression in human cancer cell lines, aiming at unveiling candidate molecular players in CA in cancer.</p>
<p>Concordantly with previous work on CA [<xref ref-type="bibr" rid="pcbi.1006832.ref007">7</xref>], we observed that high CA20 is associated with poor patient’s survival in several cancer types. Furthermore, we found a positive correlation between CA20 and hypoxic levels in glioblastoma multiforme that is particularly interesting, due to its highly hypoxic microenvironment and HIF-1α levels [<xref ref-type="bibr" rid="pcbi.1006832.ref070">70</xref>], also shown to enhance migration and invasion of its tumour cells [<xref ref-type="bibr" rid="pcbi.1006832.ref071">71</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref072">72</xref>]. Given the observed association between CA and invasion of tumour cells [<xref ref-type="bibr" rid="pcbi.1006832.ref015">15</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref017">17</xref>], an exciting hypothesis is hypoxia-induced invasion being mediated through CA. When looking at the tumour cellular composition, we found that tumours with high CA20 have lower stromal and immune cell infiltration, although the latter is not independent of tumour genomic instability and proliferation rate. Detailed studies aiming to decouple these effects could provide relevant molecular insights when considering immunotherapy, alone or in combination with genotoxic and/or anti-proliferative therapeutic approaches. Moreover, by pioneering the integration of drug sensitivity with drug perturbation profiles in human cancer cell lines, we identify candidate compounds for selectively targeting cancer cells exhibiting transcriptomic evidence for CA. These compounds could be particularly useful in the treatment of cancer types we identified as having high CA and to whose current therapy patients respond poorly. For instance, their potential in specifically targeting basal-like and luminal B breast tumours could be assessed by taking advantage of resources like patient-derived tumour xenografts [<xref ref-type="bibr" rid="pcbi.1006832.ref073">73</xref>]. The observed ability of cells carrying extra centrosomes to manipulate the surrounding tumour cells and promote their invasiveness [<xref ref-type="bibr" rid="pcbi.1006832.ref015">15</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref017">17</xref>] suggests that targeting the former may be clinically more impactful. Given CA’s cancer-specificity, the compounds identified herein could underlie the development of novel targeted cancer therapeutic options.</p>
</sec>
<sec id="sec010" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec011">
<title>Ethics statement</title>
<p>The study with human samples was conducted under the national regulative law for the handling of biological specimens from tumour banks, with samples being exclusively used for research purposes in retrospective studies, and was approved by the ethics committee of the Hospital Xeral-Cies, Vigo, Spain. Informed consent was obtained from all human participants.</p>
</sec>
<sec id="sec012">
<title>TCGA dataset</title>
<p>Publicly available RNAseqV2 (quantified through RNA-seq by Expectation Maximization) [<xref ref-type="bibr" rid="pcbi.1006832.ref074">74</xref>] and clinical data for 9,721 tumour and 725 matched-normal samples from The Cancer Genome Atlas (TCGA; <ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/" xlink:type="simple">https://cancergenome.nih.gov/</ext-link>) were downloaded from Firebrowse (<ext-link ext-link-type="uri" xlink:href="http://firebrowse.org/" xlink:type="simple">http://firebrowse.org/</ext-link>). Gene expression (read counts) data were quantile-normalized using voom [<xref ref-type="bibr" rid="pcbi.1006832.ref075">75</xref>]. For each sample, the CA20 score was calculated as the sum of the across-sample (including both tumours and matched-normal samples) normalized (log2 median-centred) expression levels of the CA20 published signature genes [<xref ref-type="bibr" rid="pcbi.1006832.ref023">23</xref>]: <italic>AURKA</italic>, <italic>CCNA2</italic>, <italic>CCND1</italic>, <italic>CCNE2</italic>, <italic>CDK1</italic>, <italic>CEP63</italic>, <italic>CEP152</italic>, <italic>E2F1</italic>, <italic>E2F2</italic>, <italic>LMO4</italic>, <italic>MDM2</italic>, <italic>MYCN</italic>, <italic>NDRG1</italic>, <italic>NEK2</italic>, <italic>PIN1</italic>, <italic>PLK1</italic>, <italic>PLK4</italic>, <italic>SASS6</italic>, <italic>STIL</italic> and <italic>TUBG1</italic> (<xref ref-type="fig" rid="pcbi.1006832.g001">Fig 1a</xref>).</p>
<p>Predicted proliferation rates of each TCGA tumour sample were retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref024">24</xref>] (n = 9,568). Whole genome doubling (corresponding to 0, 1 and ≥ 2 genome doubling events in the clonal evolution of the cancer), aneuploidy (both aneuploidy score—number of altered chromosome arms—and alterations per chromosome arm) and mutation burden characterizations were retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref034">34</xref>] (n = 9,166). Since the chromosomal arm status was not available for TCGA normal samples, we have selected only those with no CNA in the chromosomal arms tested, to make sure they are intact. CNA (n = 8,879; copy number levels were derived with the GISTIC algorithm [<xref ref-type="bibr" rid="pcbi.1006832.ref076">76</xref>] and considered as CNA if having a score lower than -1 (loss) or higher than 1 (gain)) and mutation (n = 7,120; including classification as silent, missense, splice site or nonsense ones) processed data were downloaded from Firebrowse (<ext-link ext-link-type="uri" xlink:href="http://firebrowse.org/" xlink:type="simple">http://firebrowse.org/</ext-link>). Mutations were classified as likely pathogenic and pathogenic based on ClinVar database’s (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" xlink:type="simple">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>) variant summary annotation (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/variant_summary.txt.gz" xlink:type="simple">ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/variant_summary.txt.gz</ext-link>; accessed in November 12<sup>th</sup> 2018), and 5,601 likely driver mutations were obtained from the Cancer Genome Interpreter (<ext-link ext-link-type="uri" xlink:href="https://www.cancergenomeinterpreter.org/mutations" xlink:type="simple">https://www.cancergenomeinterpreter.org/mutations</ext-link>; accessed in November 12<sup>th</sup> 2018) [<xref ref-type="bibr" rid="pcbi.1006832.ref045">45</xref>]. The list of 299 cancer driver genes was retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref043">43</xref>]. Intra-tumour heterogeneity data, measured by the number of clones per sample, were retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref077">77</xref>] (n = 1,080). The mutational signature profiles were retrieved from mSignatureDB [<xref ref-type="bibr" rid="pcbi.1006832.ref048">48</xref>] (n = 9,004). The predicted fraction of stromal (stromal score) and immune (immune score) cells in TCGA tumour samples (n = 2,463) was retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref078">78</xref>]. We used the scores calculated based on RNASeqV2 expression levels. Importantly, no CA20 gene was used by the authors to infer those cell proportions [<xref ref-type="bibr" rid="pcbi.1006832.ref078">78</xref>].</p>
<p>TCGA tumour samples were analysed for hypoxic status based on expression of 95 genes included in the hypoxia 99-metagene signature [<xref ref-type="bibr" rid="pcbi.1006832.ref056">56</xref>]. The four missing genes are three (<italic>LOC149464</italic>, <italic>LOC56901</italic> and <italic>TIMM23</italic>) for which expression levels were not available and <italic>NDRG1</italic>, excluded for being part of the CA20 gene signature. The hypoxia score was calculated like the CA20 score.</p>
<p>Additional clinical information for TCGA breast tumour samples was retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref027">27</xref>].</p>
</sec>
<sec id="sec013">
<title>METABRIC dataset</title>
<p>Normalized gene expression data for 1992 primary breast tumours and 144 normal breast tissue samples from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [<xref ref-type="bibr" rid="pcbi.1006832.ref028">28</xref>] were retrieved from European Genome-Phenome Archive (EGAC00001000484). Gene expression was profiled with Illumina HT-12 v3 microarrays, with probe-level intensity values being mean-summarised per gene. The CA20 score was calculated as for the TCGA dataset. Clinical information for the same samples was downloaded from cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/" xlink:type="simple">http://www.cbioportal.org/</ext-link>) [<xref ref-type="bibr" rid="pcbi.1006832.ref079">79</xref>].</p>
</sec>
<sec id="sec014">
<title>Analyses of CA in human breast carcinoma samples</title>
<p>Quantification of CA in breast cancer samples was performed as described in [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>]. Briefly, formalin-fixed and paraffin-embedded human breast carcinoma samples were consecutively retrieved from the files of the Department of Pathology, Hospital Xeral-Cies, Vigo, Spain. This series comprises 29 luminal A, 3 luminal B, 3 HER2 and 13 basal-like tumours. Some of these samples had already been used in one of our recent studies [<xref ref-type="bibr" rid="pcbi.1006832.ref026">26</xref>]. The status of the oestrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (HER2), antigen Ki67, and the basal markers epidermal growth factor receptor, cytokeratin 5, cytokeratin 14, P-cadherin and Vimentin was previously characterized for all tumour cases. According to their immunoprofile, breast tumour samples were classified as luminal A (ER+, PR+, HER2− and Ki67−), luminal B (ER+, PR+, HER2 overexpressing or Ki67+), HER2 (ER-, PR-, HER2 overexpressing) or basal-like carcinomas (ER−, PR−, HER2−, basal marker+). Representative tumour areas were carefully selected and at least two tissue cores (0.6 mm in diameter) were deposited into a tissue microarray. This study was conducted under the national regulative law for the handling of biological specimens from tumour banks, with samples being exclusively used for research purposes in retrospective studies. Informed consent was obtained from all human participants.</p>
<p>For immunofluorescence staining, 3 μm-thick tissue sections were deparaffinised in Clear-Rite-3 (Thermo Scientific, USA, CA) and rehydrated using a series of solutions with decreasing concentrations of ethanol. High temperature (98 °C, 60 min) antigenic retrieval with Tris-EDTA pH = 9.0 (LeicaBio systems, UK) was performed, followed by incubation with UltraVision protein block (Thermo Scientific) for 30 min at room temperature. The slides were, afterwards, incubated with mouse anti-GT335 (1/800 dilution, Adipogen Ref. AG- 20B-0020-C100) and rabbit anti-pericentrin (1/250 dilution, Abcam AB4448) in UltraAb diluent (Thermo Scientific) overnight at 4 °C. The sections were then washed three times, 5 min per wash, with 1× PBS + 0.02% Tween20 before a 1 h room temperature incubation with the secondary antibodies, anti-IgG rabbit coupled to Alexa 488 and anti-IgG mouse coupled to Alexa-594 (Invitrogen), diluted at 1/500 in PBS. Finally, sections were washed extensively with 1× PBS + 0.02% Tween20 and then counterstained and mounted with Vectashield containing DAPI (VectorLabs, CA, USA).</p>
<p>Imaging was performed on a Zeiss Imager Z1 inverted microscope, equipped with an AxioCam MRm camera (Zeiss) and ApoTome (Zeiss), using the ×100 1.4 NA Oil immersion objective. Images were taken as Z-stacks in a range of 10–14 μm, with a distance between planes of 0.3 μm, and were deconvolved with AxioVision 4.8.1 software (Zeiss). Only the structures positive for GT335 (centriolar marker) and pericentrin (PCM marker) were analysed and scored. Between 5 and 107 cells were analysed for each patient and cells with more than 4 centrioles were considered as having CA (<xref ref-type="supplementary-material" rid="pcbi.1006832.s021">S4 Table</xref>).</p>
</sec>
<sec id="sec015">
<title>CTRP dataset</title>
<p>Normalized gene-level expression and drug sensitivity (n = 481 compounds) data for 823 human cancer cell lines from the Cancer Therapeutics Response Portal (CTRP) v2 were retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref058">58</xref>]. The CA20 score was calculated as for the aforementioned datasets. Compounds with more than 20% of missing data (n = 127) were removed from the analyses. Area Under the dose-response Curve (AUC) was used as the metric of cell line’s drug sensitivity, measured over a 16-point concentration range. Note that lower AUC means higher drug activity.</p>
</sec>
<sec id="sec016">
<title>Connectivity Map dataset</title>
<p>The Connectivity Map (CMap) database of signatures [<xref ref-type="bibr" rid="pcbi.1006832.ref049">49</xref>] was interrogated using CA20 genes as an individual query in the CLUE L1000 tool (<ext-link ext-link-type="uri" xlink:href="https://clue.io/l1000-query#individual" xlink:type="simple">https://clue.io/l1000-query#individual</ext-link>, login required; CA20 genes were used as putative UP-regulated genes). For each of the 9 human cancer cell lines profiled within the Touchstone dataset (PC3, VCAP, A375, A549, HA1E, HCC515, HT29, MCF7 and HEPG2), a connectivity score was computed per perturbation (gene knock-down, gene overexpression, small molecule administration) [<xref ref-type="bibr" rid="pcbi.1006832.ref049">49</xref>], reflecting its effect on the expression of CA20 genes (except for <italic>SASS6</italic>, not profiled in this dataset). We calculated an average connectivity score per perturbation by averaging the 9 cell lines’ connectivity scores in order to have a more robust connectivity score that can be used across different cell types and tissues. Two types of perturbations were analysed: 3,799 gene knock-downs and 2,837 compounds. The Broad compound ID was used to match the 164 compounds tested by CMap and CTRP, so that the results of the analyses of the two datasets could be combined.</p>
</sec>
<sec id="sec017">
<title>Multiciliogenesis datasets</title>
<p>Normalized gene expression data for adult mouse airway epithelial cells during multiciliogenesis (triplicates for three different time points: days 0, 2 and 4) was retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref080">80</xref>] (GEO dataset accession GSE73331). The CA20 score was calculated as for the TCGA dataset.</p>
<p>The transcriptomic alterations between non-ciliating mouse tracheal epithelial cells and those undergoing differentiation, through transition to an air-liquid interface culture (ALI), and harvested at four (ALI+4) or twelve (ALI+12) days, were retrieved from [<xref ref-type="bibr" rid="pcbi.1006832.ref081">81</xref>]. Those probe-level transcriptomic alterations were mean-summarised per gene.</p>
</sec>
<sec id="sec018">
<title>Spearman’s correlation</title>
<p>Spearman’s correlations were performed using the <italic>cor</italic>.<italic>test</italic> R function (method = ‘‘spearman”) [<xref ref-type="bibr" rid="pcbi.1006832.ref082">82</xref>]. The difference between two Spearman’s correlations was tested using the <italic>paired</italic>.<italic>r</italic> function from R package <italic>psych</italic> [<xref ref-type="bibr" rid="pcbi.1006832.ref083">83</xref>].</p>
</sec>
<sec id="sec019">
<title>Unpaired two-sample statistical analyses</title>
<p>Wilcoxon rank-sum tests were performed using the <italic>wilcox</italic>.<italic>test</italic> R function [<xref ref-type="bibr" rid="pcbi.1006832.ref082">82</xref>].</p>
</sec>
<sec id="sec020">
<title>Linear regression analyses</title>
<p>Multiple linear regression modelling was implemented using the <italic>lm</italic> function from R package <italic>limma</italic> [<xref ref-type="bibr" rid="pcbi.1006832.ref084">84</xref>]. Covariate collinearity was tested using the <italic>corvif</italic> function from [<xref ref-type="bibr" rid="pcbi.1006832.ref085">85</xref>], in which all covariates had a variance inflation factor below 2. All equations and respective statistics are shown in <xref ref-type="supplementary-material" rid="pcbi.1006832.s019">S2 Table</xref>.</p>
<p>We have normalised the genomic instability covariates using z-scores (number of standard deviations from the mean) to account for differences in the prevalence of aneuploidy, mutation burden, CNA and number of clones per cohort.</p>
</sec>
<sec id="sec021">
<title>Fligner-Killeen test of homogeneity of variances</title>
<p>Fligner-Killeen test was implemented using the <italic>fligner</italic>.<italic>test</italic> R function [<xref ref-type="bibr" rid="pcbi.1006832.ref082">82</xref>].</p>
</sec>
<sec id="sec022">
<title>Test of equal proportions</title>
<p>Proportions tests were performed using the <italic>prop</italic>.<italic>test</italic> R function [<xref ref-type="bibr" rid="pcbi.1006832.ref082">82</xref>].</p>
</sec>
<sec id="sec023">
<title>Two-way analysis of variance (ANOVA)</title>
<p>Two-way ANOVA was done using the <italic>aov</italic> R function [<xref ref-type="bibr" rid="pcbi.1006832.ref082">82</xref>].</p>
</sec>
<sec id="sec024">
<title>Hierarchical clustering analyses</title>
<p>Unsupervised hierarchical clustering of the multiple linear regression results per cancer type was performed using the <italic>heatmap</italic>.<italic>2</italic> function from R package <italic>gplots</italic> [<xref ref-type="bibr" rid="pcbi.1006832.ref086">86</xref>].</p>
</sec>
<sec id="sec025">
<title>Gene Set Enrichment Analyses</title>
<p>Genes ranked according to the knock-down connectivity score were analysed for pathway enrichment using Gene Set Enrichment Analysis [<xref ref-type="bibr" rid="pcbi.1006832.ref041">41</xref>,<xref ref-type="bibr" rid="pcbi.1006832.ref042">42</xref>] with default parameters. We used a list of 299 cancer driver genes from [<xref ref-type="bibr" rid="pcbi.1006832.ref043">43</xref>], a manually curated list of centriole duplication factors (93 genes, including 10 from the CA20 signature; <xref ref-type="supplementary-material" rid="pcbi.1006832.s027">S10 Table</xref>), gene sets retrieved from the KEGG pathway database (<ext-link ext-link-type="uri" xlink:href="https://www.kegg.jp/" xlink:type="simple">https://www.kegg.jp/</ext-link>) and the MSigDB’s Hallmark Gene Sets library [<xref ref-type="bibr" rid="pcbi.1006832.ref050">50</xref>]. Those with a False Discovery Rate (FDR) lower than 5% were considered significant.</p>
</sec>
<sec id="sec026">
<title>Survival analyses</title>
<p>Dividing patients into two subgroups by CA20 median value, the significance of differences in prognostic was estimated using Kaplan−Meier plots and log-rank tests, per cancer type, through R package <italic>survival</italic> [<xref ref-type="bibr" rid="pcbi.1006832.ref087">87</xref>].</p>
</sec>
<sec id="sec027">
<title>Q-Q plot of p-values</title>
<p>To calculate the expected Spearman’s correlation coefficients and p-values used in the quantile-quantile (Q-Q) plot (<xref ref-type="supplementary-material" rid="pcbi.1006832.s014">S14 Fig</xref>), we permutated 1000 times the drug-sensitivity (in AUC) of all compounds across cell lines and, for each permutated dataset, we calculated the respective CA20-AUC Spearman’s correlations. The expected values were obtained by median-summarizing the ranked 1000 permutations’ results.</p>
<sec id="sec028">
<title>Code availability</title>
<p>All the core code generated and used in this study is available on GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/bernardo-de-almeida/PanCancer_CentrosomeAmplification" xlink:type="simple">https://github.com/bernardo-de-almeida/PanCancer_CentrosomeAmplification</ext-link>).</p>
</sec>
</sec>
</sec>
<sec id="sec029">
<title>Supporting information</title>
<supplementary-material id="pcbi.1006832.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Pan-cancer analyses of centrosome amplification-associated gene expression.</title>
<p>(<bold>a</bold>) CA20 is correlated with proliferation rate. Smooth scatter plots showing correlation between CA20 score and predicted proliferation rate [1/h] across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.4, p-value &lt; 2.2e-16). (<bold>b</bold>) CA20 score distribution across different types of kidney, brain, melanoma and lung cancers. Black points and lines represent the median +/- upper/lower quartiles. Number of samples used in each violin is shown within brackets. **** p-value &lt; 0.0001 and n.s. non-significant (Wilcoxon rank-sum test). (<bold>c</bold>) CA20 score distribution between adenocarcinoma and squamous cell carcinomas within cervical (CESC) and oesophageal (ESCA) cancer types. Black points and lines represent the median +/- upper/lower quartiles. Number of samples used in each violin is shown within brackets. ** p-value &lt; 0.01 and *** p-value &lt; 0.001 (Wilcoxon rank-sum test). CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; COADREAD: colon and rectum adenocarcinoma; ESCA: oesophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LGG: low-grade glioma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; UVM: uveal melanoma.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>CA20 is associated with different breast cancer clinical and molecular features.</title>
<p>(<bold>a-c</bold>) CA20 score distribution per (a) histological and (b) PAM50 molecular subtype, and (c) tumour stage for TCGA breast cancer samples. For each category, samples were divided in low and high proliferation groups based on median predicted proliferation rate. Only samples with proliferation information were used. * p-value &lt; 0.05, ** p-value &lt; 0.01, *** p-value &lt; 0.001, **** p-value &lt; 0.0001 and n.s. non-significant (Wilcoxon rank-sum test). (<bold>d-h</bold>) CA20 score distribution between breast tumour histological subtypes grouped by triple-negative (TNBC) status (<bold>d</bold>,<bold>f</bold>), tumour stage (<bold>e</bold>,<bold>g</bold>), or integrative clusters (<bold>h</bold>, only for METABRIC samples) for (<bold>d</bold>,<bold>e</bold>) TCGA breast cancer and (<bold>f</bold>-<bold>h</bold>) METABRIC samples. Black points and lines represent the median +/- upper/lower quartiles. * p-value &lt; 0.05, ** p-value &lt; 0.01, **** p-value &lt; 0.0001 and n.s. non-significant (Wilcoxon rank-sum test).</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Luminal B and basal-like human breast carcinomas display higher levels of centrosome amplification.</title>
<p>Distribution of the number of centrioles per cell observed in breast tumours from the different PAM50 molecular subtypes. Violin plots were created based on segments connecting frequencies at each integer (from 1 to 14 centrioles per cell), given that centriole number is a discrete variable. The number of cells analysed in the study, for each molecular subtype, is shown. ** p-value &lt; 0.01, **** p-value &lt; 0.0001 and n.s. non-significant (Wilcoxon rank-sum test).</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s004" xlink:type="simple">
<label>S4 Fig</label>
<caption>
<title>CA20 is strongly associated with chromosomal deletions independently of <italic>TP53</italic> mutations.</title>
<p>(<bold>a</bold> and <bold>b</bold>) CA20 is associated with both chromosomal deletions and amplifications. Smooth scatter plots showing correlation between CA20 score and number of (<bold>a</bold>) amplifications and (<bold>b</bold>) deletions across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.41 and 0.36, respectively, p-value &lt; 2.2e-16 for both). (<bold>c</bold>) CA20 is more strongly associated with chromosomal deletions. Smooth scatter plot showing correlation between CA20 score and the significance of the difference between the proportion of both features per sample across TCGA tumour samples (Spearman’s correlation coefficient, r = -0.1, p-value &lt; 2.2e-16). The Y-axis represents the log10 of p-value for proportion tests, with positive or negative sign if the sample has higher proportion of amplifications or deletions, respectively. (<bold>d</bold>) Significance of the difference between the proportion of amplifications and deletions per sample (from <bold>c</bold>) in all (n = 8,092), <italic>TP53</italic> wild-type (n = 6,292) or <italic>TP53</italic> mutated (n = 1,080) TCGA tumour samples divided in low and high CA20 groups (based on CA20’s median). Black points and lines represent the median +/- upper/lower quartiles. * p-value &lt; 0.05 and **** p-value &lt; 0.0001 (Wilcoxon rank-sum test). Interaction between CA20 group and <italic>TP53</italic> status was assessed by two-way ANOVA (p-value = 0.6). (<bold>e</bold>) Number of amplifications (red) and deletions (blue) in all (n = 8,092), <italic>TP53</italic> wild-type (n = 6,292) or <italic>TP53</italic> mutated (n = 1,080) TCGA tumour samples divided in low and high CA20 groups (based on CA20’s median). Black points and lines represent the median +/- upper/lower quartiles. **** p-value &lt; 0.0001 (Wilcoxon rank-sum test).</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s005" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s005" xlink:type="simple">
<label>S5 Fig</label>
<caption>
<title>CA20 is pan-cancer-widely associated with deletion of chromosome arm 5q.</title>
<p>Box plots of CA20 score per alteration (deletion, none, or amplification) on chromosome arm 5q within samples from (<bold>a</bold>) the TCGA breast cancer cohort and (<bold>b</bold>) all other TCGA cohorts. **** p-value &lt; 0.0001 (linear regression).</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s006" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s006" xlink:type="simple">
<label>S6 Fig</label>
<caption>
<title>Higher CA20 levels in TCGA normal samples whose matched tumours have alterations in 5q and 16p chromosomal arms.</title>
<p>Box plots of CA20 score of TCGA normal samples per alteration (deletion, none, or amplification) of their matched tumour samples on chromosomal arm (<bold>a</bold>) 5q (n = 297), (<bold>b</bold>) 16p (n = 566) and (<bold>c</bold>) 7p (n = 571). All normal samples used here have no CNA in the respective chromosomal arm. * p-value &lt; 0.05 and ** p-value &lt; 0.01 (Wilcoxon rank-sum test).</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s007" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s007" xlink:type="simple">
<label>S7 Fig</label>
<caption>
<title>CA20 is associated with genomic instability features independently of cell proliferation.</title>
<p>Scatter plots showing correlation between CA20 score and (<bold>a</bold>) aneuploidy score (measured as the total number of altered chromosome arms), (<bold>b</bold>) number of mutations per Mb, (<bold>c</bold>) number of CNAs and (<bold>d</bold>) clones per tumour across TCGA tumour samples divided in low and high proliferation groups (based on median predicted proliferation rate). Multivariate linear regression (CA20 ~ <italic>β</italic><sub>0</sub> + <italic>β</italic><sub>1</sub>*feature + <italic>β</italic><sub>2</sub>*proliferation group + <italic>β</italic><sub>3</sub>*cohort) p-values for each genomic feature and respective regression lines are shown. Shades around linear regression lines represent their 95% confidence interval. Only samples with information for proliferation rates were used.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s008" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s008" xlink:type="simple">
<label>S8 Fig</label>
<caption>
<title>CA20 is associated with different types of mutations.</title>
<p>(<bold>a</bold>-<bold>d</bold>) Smooth scatter plots showing correlation between CA20 score and number of (<bold>a</bold>) silent, (<bold>b</bold>) missense, (<bold>c</bold>) splice site and (<bold>d</bold>) nonsense somatic mutations per Mb across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.42, 0.45, 0.29 and 0.39, respectively, p-value &lt; 2.2e-16 for all). Y-axes are in log10 scale. Only samples with at least one mutation are shown. (<bold>e</bold>-<bold>f</bold>) Scatter plots showing correlation between CA20 score and number of likely pathogenic and pathogenic (as defined in ClinVar; see <xref ref-type="sec" rid="sec010">Methods</xref> for more details) mutations in (<bold>e</bold>) all diseases or (<bold>f</bold>) only in cancer across TCGA tumour samples (Spearman’s correlation coefficient, r = 0.18 and 0.1, respectively, p-value &lt; 2.2e-16 and = 2.6e-05). Only samples with at least one mutation are shown. 5 outlier samples with more than 20 mutations (52, 39, 29, 25 and 24 mutations) in <bold>e</bold> were removed for better visualisation.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s009" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s009" xlink:type="simple">
<label>S9 Fig</label>
<caption>
<title>Distribution of genomic instability features on TCGA.</title>
<p>(<bold>a</bold> and <bold>b</bold>) Comparison of the z-score distribution of aneuploidy score, number of mutations per Mb, number of CNAs and clones per tumour (<bold>a</bold>) between and (<bold>b</bold>) within the 12 TCGA cancer types used in multiple linear regression analyses of <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3g</xref>. Black points represent the median values. BLCA: bladder urothelial carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; LGG: low-grade glioma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PRAD: prostate adenocarcinoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; THCA: thyroid carcinoma.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s010" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s010" xlink:type="simple">
<label>S10 Fig</label>
<caption>
<title>Genes whose mutations are associated with CA20 are enriched in cancer driver genes, cancer-associated pathways and Wnt/β-catenin signalling.</title>
<p>(<bold>a</bold>) Gene Set Enrichment Analysis (GSEA) of genes ranked by their -log10 of linear regression p-value (from <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>) using a list of 299 cancer driver genes derived from [<xref ref-type="bibr" rid="pcbi.1006832.ref043">43</xref>]. The GSEA p-value is shown. (<bold>b</bold>) Driver mutations pan-cancer-wide associated with the CA20 score. The volcano plot shows the results of linear regression analyses comparing the CA20 score between wild-type samples and samples with driver mutations for 33 genes (at least 10 samples with driver mutations). Genes whose driver mutations are associated with higher and lower CA20 (FDR &lt; 0.05) are represented in red and blue, respectively. Box plot of CA20 score per <italic>TP53</italic> mutation status (wild-type, with passenger, or with driver mutation) is shown. (<bold>c</bold>) GSEA of genes ranked by their -log10 of linear regression p-value (from <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>) using KEGG pathways. The 15 significantly enriched (FDR &lt; 0.05) pathways are shown and those cancer-associated are highlighted in red. Positively (red) and negatively (blue) enriched pathways, with a FDR lower than 5%, are shown. (<bold>d</bold>) GSEA plot for the bladder cancer pathway (from <bold>c</bold>). The GSEA p-value is shown. (<bold>e</bold>) GSEA of genes ranked by their -log10 of linear regression p-value (from <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>) using MSigDB’s Hallmark Gene Sets. The top 10 gene sets are shown. Only the Wnt/β-catenin signalling gene set is significantly enriched (FDR &lt; 0.05; dark grey). (<bold>f</bold>) GSEA plot for the Wnt/β-catenin signalling gene set (from <bold>e</bold>). The GSEA p-value is shown.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s011" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s011" xlink:type="simple">
<label>S11 Fig</label>
<caption>
<title>Mutational signatures pan-cancer-wide associated with CA20 score.</title>
<p>Left: Significance of linear regression analyses (-log10 p-value) between CA20 and contribution of each mutational signatures. Positive and negative significant associations (FDR &lt; 0.05) are coloured in red and blue, respectively. Right: Smooth scatter plots showing correlations between CA20 score and contribution of mutational signatures 3, 13 and 4 in breast invasive carcinoma (BRCA) and lung adenocarcinoma (LUAD). Mutational process associated with each signature (in parenthesis) and linear regression p-values are shown.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s012" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s012" xlink:type="simple">
<label>S12 Fig</label>
<caption>
<title>Patterns of mutational signatures 1 and 12.</title>
<p>(<bold>a</bold> and <bold>b</bold>) Percentage of mutations attributed to each of the 96 substitutions, defined by the substitution class and sequence context immediately 5′ and 3′ to the mutated base, in mutational signatures (<bold>a</bold>) 1 and (<bold>b</bold>) 12. The probability bars for the six substitution classes are displayed in different colours. Images retrieved from <ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/signatures" xlink:type="simple">https://cancer.sanger.ac.uk/cosmic/signatures</ext-link>.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s013" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s013" xlink:type="simple">
<label>S13 Fig</label>
<caption>
<title>CA20 is associated with hypoxia and stromal and immune cell infiltration.</title>
<p>(<bold>a</bold>,<bold>b</bold>,<bold>d</bold>) Scatter plots showing correlation between CA20 score and (<bold>a</bold>) hypoxia, (<bold>b</bold>) stromal and (<bold>d</bold>) immune scores across TCGA tumour samples divided in low and high proliferation groups (based on median predicted proliferation rate). Multivariate linear regression (CA20 ~ <italic>β</italic><sub>0</sub> + <italic>β</italic><sub>1</sub>*hypoxia score + <italic>β</italic><sub>2</sub>*aneuploidy score + <italic>β</italic><sub>3</sub>*mutation burden + <italic>β</italic><sub>4</sub>*CNA + <italic>β</italic><sub>5</sub>*clones per tumour + <italic>β</italic><sub>6</sub>*proliferation rate + <italic>β</italic><sub>7</sub>*cohort or CA20 ~ <italic>β</italic><sub>0</sub> + <italic>β</italic><sub>1</sub>*stromal score + <italic>β</italic><sub>2</sub>*immune score + <italic>β</italic><sub>3</sub>*aneuploidy score + <italic>β</italic><sub>4</sub>*mutation burden + <italic>β</italic><sub>5</sub>*CNA + <italic>β</italic><sub>6</sub>*clones per tumour + <italic>β</italic><sub>7</sub>*proliferation rate + <italic>β</italic><sub>8</sub>*cohort) p-values for each feature and respective regression lines are shown. Shades around linear regression lines represent their 95% confidence interval. Only samples with information for proliferation rates and genomic instability features were used. (<bold>c</bold>) Higher CA20 is associated with lower immune cell infiltration. Smooth scatter plot showing correlation between the CA20 and the immune scores across TCGA tumour samples (Spearman’s correlation coefficient, r = -0.34, p-value &lt; 2.2e-16). (<bold>e</bold>) Higher CA20 is associated with lower immune cell infiltration in glioblastoma and higher infiltration in head and neck squamous cell carcinoma. Linear regression coefficients, representing the CA20 score dependence on the immune score, independently of genomic instability, across the TCGA cohorts with information for all covariates. Significant associations (FDR &lt; 0.05) are coloured. BLCA: bladder urothelial carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; LUAD: lung adenocarcinoma.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s014" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s014" xlink:type="simple">
<label>S14 Fig</label>
<caption>
<title>Q-Q plot of CTRP CA20-AUC Spearman's correlation results.</title>
<p>Quantile-quantile (Q-Q) plot of observed versus expected–log10 of Spearman’s correlation p-values between CA20 and drug-sensitivity (in AUC), with positive or negative sign if the correlation is positive or negative, respectively, across the Cancer Therapeutics Response Portal (CTRP) human cancer cell lines for 354 compounds. The solid line in the Q-Q plot indicates the distribution of compounds under the null hypothesis of no correlation. The compounds whose activity was associated with high and low CA20 (FDR &lt; 0.05; <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6a</xref>) are represented in blue and red, respectively.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s015" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s015" xlink:type="simple">
<label>S15 Fig</label>
<caption>
<title>Compounds that up-regulate the CA20 gene set.</title>
<p>Heatmap of CMap’s drug score, ranging from 100 (maximum CA20 up-regulation) to -100 (maximum CA20 down-regulation) per cell line. Drug average score (last column) is the mean of drug scores across cell lines. The 20 compounds with the highest drug average score are shown and ranked accordingly. Tissue of origin of human cancer cell lines: PC3: prostate; VCAP: prostate; A375: melanoma; A549: lung; HA1E: kidney; HCC515: lung; HT29: colon; MCF7: breast; HEPG2: liver.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s016" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s016" xlink:type="simple">
<label>S16 Fig</label>
<caption>
<title>Association between compounds’ targets and cell proliferation of TCGA samples.</title>
<p>We used linear regression (gene expression ~ <italic>β</italic><sub>0</sub> + <italic>β</italic><sub>1</sub>*proliferation rate + <italic>β</italic><sub>2</sub>*cohort) to calculate the association between expression of each compound’s predicted target gene (we merged compound target annotations from the CTRP and CMap datasets) and proliferation rates across TCGA primary tumour samples (<xref ref-type="supplementary-material" rid="pcbi.1006832.s032">S15 Table</xref>). (<bold>a</bold> and <bold>b</bold>) Scatter plots showing correlations between linear regression coefficient and (<bold>a</bold>) CMap’s average scores or (<bold>b</bold>) CTRP’s Spearman correlation coefficients of the respective compounds (Spearman’s correlation coefficient, r = 0.016 and -0.26, p-value = 0.84 and 9e-04, respectively). (<bold>c</bold>) As in <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6d</xref>, but with compounds coloured by the linear regression coefficient of the predicted target gene (using the strongest association when a compound has more than one target gene). The two compounds with no annotated target gene are represented in grey. (<bold>d</bold>) Example for gene <italic>RARG</italic>. Smooth scatter plot showing correlation between <italic>RARG</italic> gene expression and predicted proliferation rates of TCGA primary tumour samples. The linear regression p-value is shown.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s017" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s017" xlink:type="simple">
<label>S17 Fig</label>
<caption>
<title>CA20 is a surrogate for centriole overduplication during multiciliogenesis.</title>
<p>(<bold>a</bold>) CA20 increases from day 0 to day 2, and then decreases to day 4, during multiciliogenesis of adult mouse airway epithelial progenitors cultured in air-liquid interface (ALI). * p-value &lt; 0.05 and ** p-value &lt; 0.01 (Wilcoxon rank-sum test). Data from Mori et al., 2017. (<bold>b</bold>) Some CA20 genes (<italic>PLK4</italic>, <italic>STIL</italic>, <italic>CEP152</italic> and <italic>SASS6</italic>) are significantly upregulated only at the fourth day of multiciliogenesis. Significance of differential expression of CA20 genes between non-ciliating cells and cells undergoing multiciliogenesis harvested at four days (ALI +4), to enrich for genes involved in initial steps of centriole duplication, and twelve days (ALI+12), to enrich for genes expressed when cilia are mature [<xref ref-type="bibr" rid="pcbi.1006832.ref081">81</xref>]. The Y-axis represents the log10 of FDR-adjusted p-value for differential expression, with positive or negative sign if the sample has higher or lower expression than non-ciliating cells, respectively. Data from Hoh et al., 2012. (<bold>c</bold>) GSEA of the CA20 gene set on genes ranked by their signed log10 of FDR-adjusted p-value for differential expression, as in (b), between non-ciliating and ALI+4 or ALI+12 cells. GSEA p-values are shown.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s018" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s018" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>CA20 score across The Cancer Genome Atlas (TCGA) tumour and matched-normal samples.</title>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s019" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s019" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Results of all linear regression analyses performed in this study, except those involving multiple testing, whose results are presented in individual supplementary <xref ref-type="supplementary-material" rid="pcbi.1006832.s022">S5</xref>, <xref ref-type="supplementary-material" rid="pcbi.1006832.s024">S7</xref>, <xref ref-type="supplementary-material" rid="pcbi.1006832.s025">S8</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006832.s032">S15</xref> Tables.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s020" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s020" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>CA20 score across METABRIC tumour and normal samples.</title>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s021" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s021" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>CA levels in human breast carcinoma samples.</title>
<p>Both the number of cells with different number of centrioles and the percentage of cells with CA (&gt;4 centrioles) are shown.</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s022" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s022" xlink:type="simple">
<label>S5 Table</label>
<caption>
<title>Results of pan-cancer-wide linear regression analyses comparing CA20 score between samples with deletion or amplification of each chromosome arm.</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3c</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s023" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s023" xlink:type="simple">
<label>S6 Table</label>
<caption>
<title>Data used in multiple linear regression analyses to identify independent associations between genomic instability features and CA20 across 1050 tumour samples (from 12 different cancer types).</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g003">Fig 3g</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s024" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s024" xlink:type="simple">
<label>S7 Table</label>
<caption>
<title>Results of pan-cancer-wide linear regression analyses comparing CA20 score between mutated and wild-type samples for 14,589 genes (mutated in at least 20 samples).</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4a</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s025" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s025" xlink:type="simple">
<label>S8 Table</label>
<caption>
<title>Results of pan-cancer-wide linear regression analyses comparing CA20 score between driver mutated and wild-type samples for 33 genes (with driver mutations in at least 10 samples).</title>
<p>Related to <xref ref-type="supplementary-material" rid="pcbi.1006832.s010">S10b Fig</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s026" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s026" xlink:type="simple">
<label>S9 Table</label>
<caption>
<title>Connectivity Map (CMap)’s knock-down scores on the CA20 gene set in human cancer cell lines for 3,799 genes.</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g004">Fig 4d</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s027" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s027" xlink:type="simple">
<label>S10 Table</label>
<caption>
<title>Manually curated list of centriole duplication factors.</title>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s028" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s028" xlink:type="simple">
<label>S11 Table</label>
<caption>
<title>Results of survival analyses across 31 TCGA cancer types with more than 40 samples.</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g005">Fig 5a</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s029" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s029" xlink:type="simple">
<label>S12 Table</label>
<caption>
<title>CA20 score across Cancer Therapeutics Response Portal human cancer cell lines.</title>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s030" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s030" xlink:type="simple">
<label>S13 Table</label>
<caption>
<title>Results of Spearman’s correlation analyses between CA20 scores and compound Area Under the dose-response Curve (AUC) across CTRP human cancer cell lines for 354 compounds.</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6a and 6d</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s031" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s031" xlink:type="simple">
<label>S14 Table</label>
<caption>
<title>Connectivity Map (CMap)’s drug scores on the CA20 gene set in human cancer cell lines for 2,837 compounds.</title>
<p>Related to <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6c and 6d</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006832.s032" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006832.s032" xlink:type="simple">
<label>S15 Table</label>
<caption>
<title>Results of linear regression analyses comparing the expression of compounds’ target genes from <xref ref-type="fig" rid="pcbi.1006832.g006">Fig 6d</xref> and proliferation rates across TCGA primary tumour samples.</title>
<p>Related to <xref ref-type="supplementary-material" rid="pcbi.1006832.s016">S16 Fig</xref>.</p>
<p>(TXT)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank all members of N.L.B.-M and M.B.-D. labs for fruitful discussions. We are thankful to Lucas Pelkmans (UZH) for advice on multiciliogenesis analyses, to Gaëlle Marteil (M.B-D. Lab, IGC) for providing the manually curated centriole duplication factors gene list and critical reading of the manuscript, as well as to Carla Lopes (M.B-D. Lab, IGC) for critical reading of the manuscript. The results published here are in part based upon data generated by The Cancer Genome Atlas (TCGA) Research Network: <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov" xlink:type="simple">http://cancergenome.nih.gov</ext-link>. This study makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium, funded by Cancer Research UK and the British Columbia Cancer Agency Branch.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1006832.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>J-W</given-names></name>, <name name-style="western"><surname>Imai</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Lian</surname> <given-names>W-N</given-names></name>, <name name-style="western"><surname>Vallee</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>S-H</given-names></name>. <article-title>Asymmetric centrosome inheritance maintains neural progenitors in the neocortex</article-title>. <source>Nature</source> <year>2009</year>; <volume>461</volume>:<fpage>947</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature08435" xlink:type="simple">10.1038/nature08435</ext-link></comment> <object-id pub-id-type="pmid">19829375</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stevens</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Raposo</surname> <given-names>AASF</given-names></name>, <name name-style="western"><surname>Basto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>St Johnston</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Raff</surname> <given-names>JW</given-names></name>. <article-title>From stem cell to embryo without centrioles</article-title>. <source>Curr Biol</source> <year>2007</year>; <volume>17</volume>:<fpage>1498</fpage>–<lpage>503</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cub.2007.07.060" xlink:type="simple">10.1016/j.cub.2007.07.060</ext-link></comment> <object-id pub-id-type="pmid">17716897</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vinogradova</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Paul</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Grimaldi</surname> <given-names>aD</given-names></name>, <name name-style="western"><surname>Loncarek</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Yampolsky</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Concerted effort of centrosomal and Golgi-derived microtubules is required for proper Golgi complex assembly but not for maintenance</article-title>. <source>Mol Biol Cell</source> <year>2012</year>; <volume>23</volume>:<fpage>820</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1091/mbc.E11-06-0550" xlink:type="simple">10.1091/mbc.E11-06-0550</ext-link></comment> <object-id pub-id-type="pmid">22262454</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bettencourt-Dias</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Glover</surname> <given-names>DM</given-names></name>. <article-title>Centrosome biogenesis and function: centrosomics brings new understanding</article-title>. <source>Nat Rev Mol Cell Biol</source> <year>2007</year>; <volume>8</volume>:<fpage>451</fpage>–<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrm2180" xlink:type="simple">10.1038/nrm2180</ext-link></comment> <object-id pub-id-type="pmid">17505520</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bornens</surname> <given-names>M</given-names></name>. <article-title>The Centrosome in Cells and Organisms</article-title>. <source>Science</source> <year>2012</year>; <volume>335</volume>:<fpage>422</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1209037" xlink:type="simple">10.1126/science.1209037</ext-link></comment> <object-id pub-id-type="pmid">22282802</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Godinho</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Pellman</surname> <given-names>D</given-names></name>. <article-title>Causes and consequences of centrosome abnormalities in cancer</article-title>. <source>Philos Trans R Soc OB</source> <year>2014</year>; <volume>369</volume>:20130467.</mixed-citation></ref>
<ref id="pcbi.1006832.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname> <given-names>JY</given-names></name>. <article-title>A clinical overview of centrosome amplification in human cancers</article-title>. <source>Int J Biol Sci</source> <year>2011</year>; <volume>7</volume>:<fpage>1122</fpage>–<lpage>44</lpage>. <object-id pub-id-type="pmid">22043171</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silkworth</surname> <given-names>WT</given-names></name>, <name name-style="western"><surname>Nardi</surname> <given-names>IK</given-names></name>, <name name-style="western"><surname>Scholl</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Cimini</surname> <given-names>D</given-names></name>. <article-title>Multipolar Spindle Pole Coalescence Is a Major Source of Kinetochore Mis-Attachment and Chromosome Mis- Segregation in Cancer Cells</article-title>. <source>PLoS One</source> <year>2009</year>; <volume>4</volume>:<fpage>e6564</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0006564" xlink:type="simple">10.1371/journal.pone.0006564</ext-link></comment> <object-id pub-id-type="pmid">19668340</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganem</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Godinho</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Pellman</surname> <given-names>D</given-names></name>. <article-title>A mechanism linking extra centrosomes to chromosomal instability</article-title>. <source>Nature</source> <year>2009</year>; <volume>460</volume>:<fpage>278</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature08136" xlink:type="simple">10.1038/nature08136</ext-link></comment> <object-id pub-id-type="pmid">19506557</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lingle</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Barrett</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Negron</surname> <given-names>VC</given-names></name>, <name name-style="western"><surname>Assoro</surname> <given-names>ABD</given-names></name>, <name name-style="western"><surname>Boeneman</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Centrosome amplification drives chromosomal instability in breast tumor development</article-title>. <source>Proc Natl Acad Sci</source> <year>2002</year>; <volume>99</volume>:<fpage>1978</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.032479999" xlink:type="simple">10.1073/pnas.032479999</ext-link></comment> <object-id pub-id-type="pmid">11830638</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Levine</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Bakker</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Boeckx</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Moyett</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vitre</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals</article-title>. <source>Dev Cell</source> <year>2017</year>; <volume>40</volume>:<fpage>1</fpage>–<lpage>10</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Serçin</surname> <given-names>Ö</given-names></name>, <name name-style="western"><surname>Larsimont</surname> <given-names>J-C</given-names></name>, <name name-style="western"><surname>Karambelas</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Marthiens</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Moers</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Boeckx</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis</article-title>. <source>Nat Cell Biol</source> <year>2015</year>; <volume>18</volume>:<fpage>100</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncb3270" xlink:type="simple">10.1038/ncb3270</ext-link></comment> <object-id pub-id-type="pmid">26595384</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coelho</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Bury</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Shahbazi</surname> <given-names>MN</given-names></name>, <name name-style="western"><surname>Liakath-ali</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tate</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Wormald</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse</article-title>. <source>Open Biol</source> <year>2015</year>; <volume>5</volume>:150209.</mixed-citation></ref>
<ref id="pcbi.1006832.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marusyk</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tabassum</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Altrock</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Almendro</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Michor</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Polyak</surname> <given-names>K</given-names></name>. <article-title>Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity</article-title>. <source>Nature</source> <year>2014</year>; <volume>514</volume>:<fpage>54</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature13556" xlink:type="simple">10.1038/nature13556</ext-link></comment> <object-id pub-id-type="pmid">25079331</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganier</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Schnerch</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Oertle</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>RYH</given-names></name>, <name name-style="western"><surname>Plodinec</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nigg</surname> <given-names>EA</given-names></name>. <article-title>Structural centrosome aberrations promote non-cell-autonomous invasiveness</article-title>. <source>EMBO J</source> <year>2018</year>; <volume>37</volume>:<fpage>e98576</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.15252/embj.201798576" xlink:type="simple">10.15252/embj.201798576</ext-link></comment> <object-id pub-id-type="pmid">29567643</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Godinho</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Picone</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Burute</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dagher</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Su</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>CT</given-names></name>, <etal>et al</etal>. <article-title>Oncogene-like induction of cellular invasion from centrosome amplification</article-title>. <source>Nature</source> <year>2014</year>; <volume>510</volume>:<fpage>167</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature13277" xlink:type="simple">10.1038/nature13277</ext-link></comment> <object-id pub-id-type="pmid">24739973</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arnandis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Monteiro</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Bridgeman</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Rajeeve</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Gadaleta</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion</article-title>. <source>Dev Cell</source> <year>2018</year>; <volume>47</volume>:<fpage>409</fpage>–<lpage>424.e9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.devcel.2018.10.026" xlink:type="simple">10.1016/j.devcel.2018.10.026</ext-link></comment> <object-id pub-id-type="pmid">30458137</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref018"><label>18</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Duensing</surname> <given-names>S</given-names></name>. <chapter-title>Analysis of centrosomes in human cancer</chapter-title>. <source>Methods Cell Biol</source>., <volume>vol. 129</volume>, <publisher-name>Elsevier</publisher-name>; <year>2015</year>, p. <fpage>51</fpage>–<lpage>60</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Farahani</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Braun</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jutt</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Huffman</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Reder</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Three-dimensional Imaging and Scanning: Current and Future Applications for Pathology</article-title>. <source>J Pathol Inform</source> <year>2017</year>; <volume>8</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chng</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Braggio</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mulligan</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bryant</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Remstein</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Valdez</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition</article-title>. <source>Blood</source> <year>2008</year>; <volume>111</volume>:<fpage>1603</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2007-06-097774" xlink:type="simple">10.1182/blood-2007-06-097774</ext-link></comment> <object-id pub-id-type="pmid">18006703</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chng</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Ahmann</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Henderson</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Santana-davila</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Greipp</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Gertz</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Clinical implication of centrosome amplification in plasma cell neoplasm</article-title>. <source>Blood</source> <year>2006</year>; <volume>107</volume>:<fpage>3669</fpage>–<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2005-09-3810" xlink:type="simple">10.1182/blood-2005-09-3810</ext-link></comment> <object-id pub-id-type="pmid">16373658</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pannu</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Mittal</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Cantuaria</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Reid</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Donthamsetty</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers</article-title>. <source>Oncotarget</source> <year>2015</year>; <volume>6</volume>:<fpage>10487</fpage>–<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.3402" xlink:type="simple">10.18632/oncotarget.3402</ext-link></comment> <object-id pub-id-type="pmid">25868856</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ogden</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rida</surname> <given-names>PCG</given-names></name>, <name name-style="western"><surname>Aneja</surname> <given-names>R</given-names></name>. <article-title>Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors</article-title>. <source>Sci Rep</source> <year>2017</year>; <volume>7</volume>:<fpage>262</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-017-00363-w" xlink:type="simple">10.1038/s41598-017-00363-w</ext-link></comment> <object-id pub-id-type="pmid">28325915</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diener</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Resendis-Antonio</surname> <given-names>O</given-names></name>. <article-title>Personalized Prediction of Proliferation Rates and Metabolic Liabilities in Cancer Biopsies</article-title>. <source>Front Physiol</source> <year>2016</year>; <volume>7</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ogden</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rida</surname> <given-names>PCG</given-names></name>, <name name-style="western"><surname>Aneja</surname> <given-names>R</given-names></name>. <article-title>Centrosome amplification: a suspect in breast cancer and racial disparities</article-title>. <source>Endocr Relat Cancer</source> <year>2017</year>; <volume>24</volume>:<fpage>T47</fpage>–<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1530/ERC-17-0072" xlink:type="simple">10.1530/ERC-17-0072</ext-link></comment> <object-id pub-id-type="pmid">28515047</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marteil</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Guerrero</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vieira</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>de Almeida</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Machado</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mendonça</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation</article-title>. <source>Nat Commun</source> <year>2018</year>; <volume>9</volume>:<fpage>1258</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-018-03641-x" xlink:type="simple">10.1038/s41467-018-03641-x</ext-link></comment> <object-id pub-id-type="pmid">29593297</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>The Cancer Genome Atlas Network</collab>. <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source>Nature</source> <year>2012</year>; <volume>490</volume>:<fpage>61</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature11412" xlink:type="simple">10.1038/nature11412</ext-link></comment> <object-id pub-id-type="pmid">23000897</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Curtis</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Chin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Turashvili</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Rueda</surname> <given-names>OM</given-names></name>, <name name-style="western"><surname>Dunning</surname> <given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups</article-title>. <source>Nature</source> <year>2012</year>; <volume>486</volume>:<fpage>346</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature10983" xlink:type="simple">10.1038/nature10983</ext-link></comment> <object-id pub-id-type="pmid">22522925</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Denu</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Zasadil</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Kanugh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Laffin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Weaver</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Burkard</surname> <given-names>ME</given-names></name>. <article-title>Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer</article-title>. <source>BMC Cancer</source> <year>2016</year>; <volume>16</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barroso-Sousa</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Metzger-Filho</surname> <given-names>O</given-names></name>. <article-title>Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications</article-title>. <source>Ther Adv Med Oncol</source> <year>2016</year>; <volume>8</volume>:<fpage>261</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1758834016644156" xlink:type="simple">10.1177/1758834016644156</ext-link></comment> <object-id pub-id-type="pmid">27482285</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parker</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Mullins</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cheang</surname> <given-names>MCU</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Voduc</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Vickery</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title>. <source>J Clin Oncol</source> <year>2009</year>; <volume>27</volume>:<fpage>1160</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2008.18.1370" xlink:type="simple">10.1200/JCO.2008.18.1370</ext-link></comment> <object-id pub-id-type="pmid">19204204</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Holland</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Cleveland</surname> <given-names>DW</given-names></name>. <article-title>Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis</article-title>. <source>Nat Rev Mol Cell Biol</source> <year>2009</year>; <volume>10</volume>:<fpage>478</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrm2718" xlink:type="simple">10.1038/nrm2718</ext-link></comment> <object-id pub-id-type="pmid">19546858</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boveri</surname> <given-names>T</given-names></name>. <article-title>Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris</article-title>. <source>J Cell Sci</source> <year>2008</year>; <volume>121</volume>:<fpage>1</fpage>–<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1242/jcs.025742" xlink:type="simple">10.1242/jcs.025742</ext-link></comment> <object-id pub-id-type="pmid">18089652</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taylor</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Shih</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ha</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Berger</surname> <given-names>AC</given-names></name>, <etal>et al</etal>. <article-title>Genomic and Functional Approaches to Understanding Cancer Aneuploidy</article-title>. <source>Cancer Cell</source> <year>2018</year>; <volume>33</volume>:<fpage>676</fpage>–<lpage>89</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ccell.2018.03.007" xlink:type="simple">10.1016/j.ccell.2018.03.007</ext-link></comment> <object-id pub-id-type="pmid">29622463</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopes</surname> <given-names>CAM</given-names></name>, <name name-style="western"><surname>Mesquita</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cunha</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Cardoso</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Carapeta</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Laranjeira</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Centrosome amplification arises before neoplasia and increases upon p53 loss in tumorigenesis</article-title>. <source>J Cell Biol</source> <year>2018</year>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref036"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Laks E, Zahn H, Lai D, McPherson A, Steif A, Brimhall J, et al. Resource: Scalable whole genome sequencing of 40,000 single cells identifies stochastic aneuploidies, genome replication states and clonal repertoires. BioRxiv 2018.</mixed-citation></ref>
<ref id="pcbi.1006832.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Kanaan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Baed</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Gabrielson</surname> <given-names>E</given-names></name>. <article-title>Chromosomal changes in aggressive breast cancers with basal-like features</article-title>. <source>Cancer Genet Cytogenet</source> <year>2009</year>; <volume>193</volume>:<fpage>29</fpage>–<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cancergencyto.2009.03.017" xlink:type="simple">10.1016/j.cancergencyto.2009.03.017</ext-link></comment> <object-id pub-id-type="pmid">19602461</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gillette</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Clauser</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Cao</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Petralia</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Proteogenomics connects somatic mutations to signalling in breast cancer</article-title>. <source>Nature</source> <year>2016</year>; <volume>534</volume>:<fpage>55</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature18003" xlink:type="simple">10.1038/nature18003</ext-link></comment> <object-id pub-id-type="pmid">27251275</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silva</surname> <given-names>GO</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Parker</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Gatza</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Carey</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer</article-title>. <source>Breast Cancer Res Treat</source> <year>2015</year>; <volume>152</volume>:<fpage>347</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10549-015-3476-2" xlink:type="simple">10.1007/s10549-015-3476-2</ext-link></comment> <object-id pub-id-type="pmid">26109346</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weigman</surname> <given-names>VJ</given-names></name>, <name name-style="western"><surname>Chao</surname> <given-names>H-H</given-names></name>, <name name-style="western"><surname>Shabalin</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Parker</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Nordgard</surname> <given-names>SH</given-names></name>, <etal>et al</etal>. <article-title>Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival</article-title>. <source>Breast Cancer Res Treat</source> <year>2012</year>; <volume>133</volume>:<fpage>865</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10549-011-1846-y" xlink:type="simple">10.1007/s10549-011-1846-y</ext-link></comment> <object-id pub-id-type="pmid">22048815</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Subramanian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tamayo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mootha</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Mukherjee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ebert</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Gillette</surname> <given-names>M a</given-names></name>, <etal>et al</etal>. <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2005</year>; <volume>102</volume>:<fpage>15545</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0506580102" xlink:type="simple">10.1073/pnas.0506580102</ext-link></comment> <object-id pub-id-type="pmid">16199517</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mootha</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Lindgren</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Eriksson</surname> <given-names>K-F</given-names></name>, <name name-style="western"><surname>Subramanian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sihag</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lehar</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>34</volume>:<fpage>267</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng1180" xlink:type="simple">10.1038/ng1180</ext-link></comment> <object-id pub-id-type="pmid">12808457</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bailey</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Tokheim</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Porta-Pardo</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sengupta</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bertrand</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weerasinghe</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Comprehensive Characterization of Cancer Driver Genes and Mutations</article-title>. <source>Cell</source> <year>2018</year>; <volume>173</volume>:<fpage>371</fpage>–<lpage>385.e18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2018.02.060" xlink:type="simple">10.1016/j.cell.2018.02.060</ext-link></comment> <object-id pub-id-type="pmid">29625053</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iovino</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lentini</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Amato</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Di Leonardo</surname> <given-names>A</given-names></name>. <article-title>RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts</article-title>. <source>Mol Cancer</source> <year>2006</year>; <volume>5</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tamborero</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Rubio-Perez</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Deu-Pons</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Schroeder</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Vivancos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rovira</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Cancer Genome Interpreter Annotates The Biological And Clinical Relevance Of Tumor Alterations</article-title>. <source>Genome Med</source> <year>2018</year>; <volume>10</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rhys</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Monteiro</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Vaghela</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Arnandis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kato</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Loss of E-cadherin provides tolerance to centrosome amplification in epithelial cancer cells</article-title>. <source>J Cell Biol</source> <year>2017</year>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alexandrov</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Stratton</surname> <given-names>MR</given-names></name>. <article-title>Mutational signatures: The patterns of somatic mutations hidden in cancer genomes</article-title>. <source>Curr Opin Genet Dev</source> <year>2014</year>; <volume>24</volume>:<fpage>52</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gde.2013.11.014" xlink:type="simple">10.1016/j.gde.2013.11.014</ext-link></comment> <object-id pub-id-type="pmid">24657537</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Chiu</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Yeh</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Chiu</surname> <given-names>CH</given-names></name>, <etal>et al</etal>. <article-title>MSignatureDB: A database for deciphering mutational signatures in human cancers</article-title>. <source>Nucleic Acids Res</source> <year>2018</year>; <volume>46</volume>:<fpage>D964</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkx1133" xlink:type="simple">10.1093/nar/gkx1133</ext-link></comment> <object-id pub-id-type="pmid">29145625</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Subramanian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Narayan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Corsello</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Peck</surname> <given-names>DD</given-names></name>, <name name-style="western"><surname>Natoli</surname> <given-names>TE</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>X</given-names></name>, <etal>et al</etal>. <article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title>. <source>Cell</source> <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2017.10.049" xlink:type="simple">10.1016/j.cell.2017.10.049</ext-link></comment> <object-id pub-id-type="pmid">29195078</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liberzon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Birger</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ghandi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mesirov</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Tamayo</surname> <given-names>P</given-names></name>. <article-title>The Molecular Signatures Database Hallmark Gene Set Collection</article-title>. <source>Cell Syst</source> <year>2015</year>; <volume>1</volume>:<fpage>417</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cels.2015.12.004" xlink:type="simple">10.1016/j.cels.2015.12.004</ext-link></comment> <object-id pub-id-type="pmid">26771021</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rankin</surname> <given-names>EB</given-names></name>, <name name-style="western"><surname>Giaccia</surname> <given-names>AJ</given-names></name>. <article-title>Hypoxic control of metastasis</article-title>. <source>Science</source> <year>2016</year>; <volume>352</volume>:<fpage>175</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aaf4405" xlink:type="simple">10.1126/science.aaf4405</ext-link></comment> <object-id pub-id-type="pmid">27124451</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luoto</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Kumareswaran</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bristow</surname> <given-names>RG</given-names></name>. <article-title>Tumor hypoxia as a driving force in genetic instability</article-title>. <source>Genome Integr</source> <year>2013</year>; <volume>4</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Petrova</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Annicchiarico-petruzzelli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Melino</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Amelio</surname> <given-names>I</given-names></name>. <article-title>The hypoxic tumour microenvironment</article-title>. <source>Oncogenesis</source> <year>2018</year>; <volume>7</volume>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mittal</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Ogden</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Donthamsetty</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Melton</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Gupta</surname> <given-names>M V</given-names></name>., <etal>et al</etal>. <article-title>Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells</article-title>. <source>Sci Rep</source> <year>2017</year>; <volume>7</volume>:<fpage>43984</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep43984" xlink:type="simple">10.1038/srep43984</ext-link></comment> <object-id pub-id-type="pmid">28272508</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref055"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Mittal K, Choi D, Maganti N, Ogden A, Melton B, Kaur J, et al. Hypoxia induced centrosome amplification via HIF-1α/Plk4 signaling axis associates with poorer overall survival in TNBC [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-01-23. 2018.</mixed-citation></ref>
<ref id="pcbi.1006832.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Winter</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Buffa</surname> <given-names>FM</given-names></name>, <name name-style="western"><surname>Silva</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Valentine</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Turley</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers</article-title>. <source>Cancer Res</source> <year>2007</year>; <volume>67</volume>:<fpage>3441</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-06-3322" xlink:type="simple">10.1158/0008-5472.CAN-06-3322</ext-link></comment> <object-id pub-id-type="pmid">17409455</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hanahan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weinberg</surname> <given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source> <year>2011</year>; <volume>144</volume>:<fpage>646</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2011.02.013" xlink:type="simple">10.1016/j.cell.2011.02.013</ext-link></comment> <object-id pub-id-type="pmid">21376230</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rees</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Seashore-ludlow</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Cheah</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Price</surname> <given-names>E V</given-names></name>, <name name-style="western"><surname>Gill</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat Chem Biol</source> <year>2016</year>; <volume>12</volume>:<fpage>109</fpage>–<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nchembio.1986" xlink:type="simple">10.1038/nchembio.1986</ext-link></comment> <object-id pub-id-type="pmid">26656090</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Erikson</surname> <given-names>RL</given-names></name>. <article-title>Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA</article-title>. <source>Proc Natl Acad Sci</source> <year>2002</year>; <volume>99</volume>:<fpage>8672</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.132269599" xlink:type="simple">10.1073/pnas.132269599</ext-link></comment> <object-id pub-id-type="pmid">12077309</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Izumi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ikeuchi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Saya</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kajii</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Matsuura</surname> <given-names>S</given-names></name>. <article-title>BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells</article-title>. <source>Oncogene</source> <year>2009</year>; <volume>28</volume>:<fpage>2806</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/onc.2009.141" xlink:type="simple">10.1038/onc.2009.141</ext-link></comment> <object-id pub-id-type="pmid">19503101</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vladar</surname> <given-names>EK</given-names></name>, <name name-style="western"><surname>Stearns</surname> <given-names>T</given-names></name>. <article-title>Molecular characterization of centriole assembly in ciliated epithelial cells</article-title>. <source>J Cell Biol</source> <year>2007</year>; <volume>178</volume>:<fpage>31</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1083/jcb.200703064" xlink:type="simple">10.1083/jcb.200703064</ext-link></comment> <object-id pub-id-type="pmid">17606865</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Worrall</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Tamura</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Mazzagatti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vladimirou</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Foijer</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mcclelland</surname> <given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>Non-random Mis-segregation of Human Chromosomes</article-title>. <source>Cell Rep</source> <year>2018</year>; <volume>23</volume>:<fpage>3366</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2018.05.047" xlink:type="simple">10.1016/j.celrep.2018.05.047</ext-link></comment> <object-id pub-id-type="pmid">29898405</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chichinadze</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tkemaladze</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lazarashvili</surname> <given-names>A</given-names></name>. <article-title>A New Class of RNAs and the Centrosomal Hypothesis of Cell Aging</article-title>. <source>Adv Gerontol</source> <year>2012</year>; <volume>2</volume>:<fpage>287</fpage>–<lpage>91</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Na</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pyo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jeon</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Arking</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Metformin inhibits age-related centrosome amplification in Drosophila midgut stem cells through AKT/TOR pathway</article-title>. <source>Mech Ageing Dev</source> <year>2015</year>; <volume>149</volume>:<fpage>8</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mad.2015.05.004" xlink:type="simple">10.1016/j.mad.2015.05.004</ext-link></comment> <object-id pub-id-type="pmid">25988874</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pyo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Na</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Jeon</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Arking</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Biochemical and Biophysical Research Communications Increased centrosome amplification in aged stem cells of the Drosophila midgut</article-title>. <source>Biochem Biophys Res Commun</source> <year>2014</year>; <volume>450</volume>:<fpage>961</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohshima</surname> <given-names>S</given-names></name>. <article-title>Centrosome Aberrations Associated with Cellular Senescence and p53 Localization at Supernumerary Centrosomes</article-title>. <source>OxidativeMedicine Cell Longev</source> <year>2012</year>; <volume>2012</volume>:217594.</mixed-citation></ref>
<ref id="pcbi.1006832.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Manning</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>S</given-names></name>. <article-title>A potential role for NEDD1 and the centrosome in senescence of mouse embryonic fibroblasts</article-title>. <source>Cell Death Dis</source> <year>2010</year>; <volume>1</volume>:<fpage>e35</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/cddis.2010.12" xlink:type="simple">10.1038/cddis.2010.12</ext-link></comment> <object-id pub-id-type="pmid">21364642</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bryja</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Červenka</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Čajánek</surname> <given-names>L</given-names></name>. <article-title>The connections of Wnt pathway components with cell cycle and centrosome: side effects or a hidden logic?</article-title> <source>Crit Rev Biochem Mol Biol</source> <year>2017</year>; <volume>52</volume>:<fpage>614</fpage>–<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/10409238.2017.1350135" xlink:type="simple">10.1080/10409238.2017.1350135</ext-link></comment> <object-id pub-id-type="pmid">28741966</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bahmanyar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Guiney</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Hatch</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Nelson</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Barth</surname> <given-names>AIM</given-names></name>. <article-title>Formation of extra centrosomal structures is dependent on b-catenin</article-title>. <source>J Cell Sci</source> <year>2010</year>; <volume>123</volume>:<fpage>3125</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1242/jcs.064782" xlink:type="simple">10.1242/jcs.064782</ext-link></comment> <object-id pub-id-type="pmid">20736306</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref070"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jawhari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ratinaud</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Verdier</surname> <given-names>M</given-names></name>. <article-title>Glioblastoma, hypoxia and autophagy: A survival-prone “ménage-à-trois.”</article-title> <source>Cell Death Dis</source> <year>2016</year>; <volume>7</volume>:<fpage>1</fpage>–<lpage>10</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref071"><label>71</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Joseph</surname> <given-names>J V.</given-names></name>, <name name-style="western"><surname>Conroy</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pavlov</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sontakke</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tomar</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Eggens-Meijer</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis</article-title>. <source>Cancer Lett</source> <year>2015</year>; <volume>359</volume>:<fpage>107</fpage>–<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canlet.2015.01.010" xlink:type="simple">10.1016/j.canlet.2015.01.010</ext-link></comment> <object-id pub-id-type="pmid">25592037</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref072"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monteiro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pilkington</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Madureira</surname> <given-names>P</given-names></name>. <article-title>The Role of Hypoxia in Glioblastoma Invasion</article-title>. <source>Cells</source> <year>2017</year>; <volume>6</volume>:<fpage>45</fpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref073"><label>73</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bruna</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rueda</surname> <given-names>OM</given-names></name>, <name name-style="western"><surname>Greenwood</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Batra</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Callari</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Batra</surname> <given-names>RN</given-names></name>, <etal>et al</etal>. <article-title>A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds</article-title>. <source>Cell</source> <year>2016</year>; <volume>167</volume>:<fpage>260</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2016.08.041" xlink:type="simple">10.1016/j.cell.2016.08.041</ext-link></comment> <object-id pub-id-type="pmid">27641504</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref074"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Dewey</surname> <given-names>CN</given-names></name>. <article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title>. <source>BMC Bioinformatics</source> <year>2011</year>; <volume>12</volume>:<fpage>323</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2105-12-323" xlink:type="simple">10.1186/1471-2105-12-323</ext-link></comment> <object-id pub-id-type="pmid">21816040</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref075"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Law</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Smyth</surname> <given-names>GK</given-names></name>. <article-title>Voom: precision weights unlock linear model analysis tools for RNA-seq read counts</article-title>. <source>Genome Biol</source> <year>2014</year>; <volume>15</volume>:<fpage>1</fpage>–<lpage>17</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref076"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mermel</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Schumacher</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Meyerson</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Beroukhim</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Getz</surname> <given-names>G</given-names></name>. <article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title>. <source>Genome Biol</source> <year>2011</year>; <volume>12</volume>:<fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref077"><label>77</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Andor</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Graham</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Jansen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Xia</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Aktipis</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Petritsch</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Pan-cancer analysis of the extent and consequences of intratumor heterogeneity</article-title>. <source>Nat Med</source> <year>2016</year>; <volume>22</volume>:<fpage>105</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.3984" xlink:type="simple">10.1038/nm.3984</ext-link></comment> <object-id pub-id-type="pmid">26618723</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref078"><label>78</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoshihara</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Shahmoradgoli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Martínez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Vegesna</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Torres-Garcia</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title>. <source>Nat Commun</source> <year>2013</year>; <volume>4</volume>:<fpage>2612</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms3612" xlink:type="simple">10.1038/ncomms3612</ext-link></comment> <object-id pub-id-type="pmid">24113773</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref079"><label>79</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cerami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dogrusoz</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Gross</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Sumer</surname> <given-names>SO</given-names></name>, <name name-style="western"><surname>Aksoy</surname> <given-names>BA</given-names></name>, <etal>et al</etal>. <article-title>The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data</article-title>. <source>Cancer Discov</source> <year>2012</year>; <volume>2</volume>:<fpage>401</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2159-8290.CD-12-0095" xlink:type="simple">10.1158/2159-8290.CD-12-0095</ext-link></comment> <object-id pub-id-type="pmid">22588877</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref080"><label>80</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mori</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hazan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Danielian</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Mahoney</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Cytoplasmic E2f4 forms organizing centres for initiation of centriole amplification during multiciliogenesis</article-title>. <source>Nat Commun</source> <year>2017</year>; <volume>8</volume>:15857.</mixed-citation></ref>
<ref id="pcbi.1006832.ref081"><label>81</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoh</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Stowe</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Turk</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Stearns</surname> <given-names>T</given-names></name>. <article-title>Transcriptional Program of Ciliated Epithelial Cells Reveals New Cilium and Centrosome Components and Links to Human Disease</article-title>. <source>PLoS One</source> <year>2012</year>; <volume>7</volume>:<fpage>e52166</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0052166" xlink:type="simple">10.1371/journal.pone.0052166</ext-link></comment> <object-id pub-id-type="pmid">23300604</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref082"><label>82</label><mixed-citation publication-type="other" xlink:type="simple">R Core Team. R: A Language and Environment for Statistical Computing 2017.</mixed-citation></ref>
<ref id="pcbi.1006832.ref083"><label>83</label><mixed-citation publication-type="other" xlink:type="simple">Revelle W. psych: Procedures for Personality and Psychological Research. R package version 1.7.8. 2017.</mixed-citation></ref>
<ref id="pcbi.1006832.ref084"><label>84</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ritchie</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Phipson</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Law</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source> <year>2015</year>; <volume>43</volume>:<fpage>e47</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkv007" xlink:type="simple">10.1093/nar/gkv007</ext-link></comment> <object-id pub-id-type="pmid">25605792</object-id></mixed-citation></ref>
<ref id="pcbi.1006832.ref085"><label>85</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Zuur</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ieno</surname> <given-names>EN</given-names></name>, <name name-style="western"><surname>Walker</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Saveliev</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>G</given-names></name>. <source>Mixed Effects Models and Extensions in Ecology with R</source>. <publisher-name>Springer</publisher-name>; <year>2009</year>.</mixed-citation></ref>
<ref id="pcbi.1006832.ref086"><label>86</label><mixed-citation publication-type="other" xlink:type="simple">Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: Various R Programming Tools for Plotting Data. R package version 3.0.1. 2016.</mixed-citation></ref>
<ref id="pcbi.1006832.ref087"><label>87</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Therneau</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Grambsch</surname> <given-names>PM</given-names></name>. <source>Modeling Survival Data: Extending the Cox Model</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2000</year>.</mixed-citation></ref>
</ref-list>
</back>
</article>